Updated on 2021/11/04

写真a

 
OKAMOTO Yasuhiro
 
Organization
Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area Graduate School of Medical and Dental Sciences Health Research Course Developmental Medicine Professor
Title
Professor
External link

Degree

  • 博士(医学) ( 1998.2   徳島大学 )

Research Areas

  • Others / Others  / 小児がん

Research History

  • Kagoshima University   Professor

    2021.4

  • Kagoshima University   Associate Professor

    2015.4 - 2021.3

Professional Memberships

  • ASCO

    2015.10

  • ASH

    2015.10

  • 日本小児血液・がん学会

    2015.10

  • 日本造血細胞移植学会

    2015.10

  • 日本血液学会

    2015.10

  • 日本小児科学会

    2015.10

▼display all

Studying abroad experiences

  • 1999.7 - 2002.6   St. Jude Children's Research Hospital   Clinical Fellow

 

Papers

  • 下村 育史, 中川 俊輔, あべ松 貴成, 櫨木 大祐, 児玉 祐一, 西川 拓朗, 岡本 康裕, 河野 嘉文 .  心原性ショックと高度腎不全で発症し、体外循環と化学療法を併用して救命できた神経芽腫 .  日本小児血液・がん学会雑誌58 ( 2 ) 166 - 170   2021.8心原性ショックと高度腎不全で発症し、体外循環と化学療法を併用して救命できた神経芽腫

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

  • 東矢 俊一郎, 古賀 友紀, 岡本 康裕, 野村 優子, 中山 秀樹, 大園 秀一, 本田 裕子, 興梠 雅彦, 西 眞範, 右田 昌宏, 興梠 健作, 舩越 康智, 末延 聡一, 齋藤 祐介, 新小田 雄一, 比嘉 猛, 百名 伸之, 唐川 修平, 武本 淳吉, 大賀 正一 .  COVID19パンデミック下における小児がん診療の現状 九州・沖縄ブロック小児がん連携病院における調査 .  日本小児血液・がん学会雑誌58 ( 2 ) 132 - 137   2021.8COVID19パンデミック下における小児がん診療の現状 九州・沖縄ブロック小児がん連携病院における調査

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

  • Takanari Abematsu, Takuro Nishikawa, Norio Shiba, Yuka Iijima-Yamashita, Yasuhiro Inaba, Yoshihiro Takahashi, Shunsuke Nakagawa, Yuichi Kodama, Yasuhiro Okamoto, Yoshifumi Kawano .  Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report. .  Pediatric blood & cancer68 ( 11 ) e29216   2021.7International journal

     More details

    Language:English  

    DOI: 10.1002/pbc.29216

    Scopus

    PubMed

  • Sugita Koshiro, Kaji Tatsuru, Muto Mitsuru, Nishikawa Takuro, Okamoto Yasuhiro, Imamura Mari, Ieiri Satoshi .  Successful laparoscopic extirpation of a vasoactive intestinal polypeptide-secreting neuroblastoma originating from the right adrenal gland: A report of an infantile case(和訳中) .  Asian Journal of Endoscopic Surgery14 ( 3 ) 611 - 614   2021.7Successful laparoscopic extirpation of a vasoactive intestinal polypeptide-secreting neuroblastoma originating from the right adrenal gland: A report of an infantile case(和訳中)

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

  • 森山 瑞葵, 西川 拓朗, 中村 達郎, あべ松 貴成, 中川 俊輔, 児玉 祐一, 岡本 康裕, 岩元 二郎, 河野 嘉文 .  Eltrombopag投与により血小板数と出血症状の改善を認めたX連鎖性血小板減少症 .  臨床血液62 ( 4 ) 257 - 261   2021.4

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    症例は,乳児期より慢性的に血小板減少を認める13歳男子。慢性血小板減少症の家族歴を有すること,小型血小板,免疫グロブリン治療に不応などより,X連鎖性血小板減少症(X-linked thrombocytopenia,XLT)を疑い,Wiskott-Aldrich syndrome蛋白(WASP)発現解析を行ったところ,発現低下を認めた。WASP遺伝子解析では,WASP-interacting protein領域のエクソン3部位のミスセンス変異[c.296A>G(p.Gln99Arg)]を認め,XLTと診断した。運動制限解除のためeltrombopagの内服を12.5mg/日で12歳時から開始した。25mg/日まで増量したところ血小板数は5万/μl前後まで上昇し,運動制限解除後も出血症状は出現しにくくなった。Eltrombopag治療後の透過型電子顕微鏡検査では血小板微細構造,凝集能検査の異常を認めていた。XLT症例に対するeltrombopag治療は,血小板数増加,出血症状の改善を期待できる。(著者抄録)

  • 森山 瑞葵, 西川 拓朗, 中村 達郎, あべ松 貴成, 中川 俊輔, 児玉 祐一, 岡本 康裕, 岩元 二郎, 河野 嘉文 .  Eltrombopag投与により血小板数と出血症状の改善を認めたX連鎖性血小板減少症 .  臨床血液62 ( 4 ) 257 - 261   2021.4Eltrombopag投与により血小板数と出血症状の改善を認めたX連鎖性血小板減少症

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    症例は,乳児期より慢性的に血小板減少を認める13歳男子。慢性血小板減少症の家族歴を有すること,小型血小板,免疫グロブリン治療に不応などより,X連鎖性血小板減少症(X-linked thrombocytopenia,XLT)を疑い,Wiskott-Aldrich syndrome蛋白(WASP)発現解析を行ったところ,発現低下を認めた。WASP遺伝子解析では,WASP-interacting protein領域のエクソン3部位のミスセンス変異[c.296A>G(p.Gln99Arg)]を認め,XLTと診断した。運動制限解除のためeltrombopagの内服を12.5mg/日で12歳時から開始した。25mg/日まで増量したところ血小板数は5万/μl前後まで上昇し,運動制限解除後も出血症状は出現しにくくなった。Eltrombopag治療後の透過型電子顕微鏡検査では血小板微細構造,凝集能検査の異常を認めていた。XLT症例に対するeltrombopag治療は,血小板数増加,出血症状の改善を期待できる。(著者抄録)

  • Shunsuke Nakagawa, Motohiro Kato, Toshihiko Imamura, Chihaya Imai, Katsuyoshi Koh, Yoshifumi Kawano, Yasuto Shimomura, Arata Watanabe, Atsushi Kikuta, Akiko Saito, Keizo Horibe, Atsushi Manabe, Akira Ohara, Yasuhiro Okamoto .  In-Hospital Management Might Reduce Induction Deaths in Pediatric Patients With Acute Lymphoblastic Leukemia: Results From a Japanese Cohort. .  Journal of pediatric hematology/oncology43 ( 2 ) 39 - 46   2021.3International journal

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Induction deaths (ID) remain a critical issue in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL). The reported rate of ID in this population is 1% or higher. We speculate that this proportion might be lower in Japan because of mandatory hospitalization during induction therapy to manage complications. We retrospectively analyzed the incidence of ID among children with ALL enrolled in 4 Japanese study groups between 1994 and 2013. Among 5620 children, 41 (0.73%) cases of ID were noted. The median age was 6.5 years; 24 children were female, and 7 had T-cell ALL. Infection was the most common cause of ID (n=22), but the incidence (0.39%) was lower than that reported in western countries. Mortality within 48 hours from the onset of infection was low, comprising 25% of infection-related deaths. The incidence of infections caused by Bacillus species was low. Only 1 patient died because of Aspergillus infection. Fatal infections mostly occurred during the third week of induction therapy. Our findings suggest that close monitoring, stringent infection control, and immediate administration of appropriate antibiotics through hospitalization might be important strategies in reducing the rate of infection-related ID in pediatric patients with ALL.

    DOI: 10.1097/MPH.0000000000001926

    Scopus

    PubMed

  • Koshiro Sugita, Tatsuru Kaji, Mitsuru Muto, Takuro Nishikawa, Yasuhiro Okamoto, Mari Imamura, Satoshi Ieiri .  Successful laparoscopic extirpation of a vasoactive intestinal polypeptide-secreting neuroblastoma originating from the right adrenal gland: A report of an infantile case .  ASIAN JOURNAL OF ENDOSCOPIC SURGERY14 ( 3 ) 611 - 614   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY  

    We herein report a 10-month-old female infant with a 4-month history of diarrhea with electrolyte abnormalities and growth impairment. A 4-cm right adrenal tumor was detected by computed tomography. No metastasis or accumulation on I-123-metaiodobenzylguanidine scintigraphy was recognized in the tumor. A vasoactive intestinal peptide-secreting neuroblastic tumor was suspected, and octreotide was started, but the diarrhea persisted. Tumor extirpation was laparoscopically performed. After tumor removal, the symptoms improved immediately, and her growth caught up by 9 months after surgery. A minimally invasive approach for pediatric solid tumor is difficult, especially for neuroblastoma, but may be beneficial for the patient's recovery.

    DOI: 10.1111/ases.12916

    Web of Science

    Scopus

    PubMed

  • Miharu Yabe, Tomohiro Morio, Ken Tabuchi, Daisuke Tomizawa, Daiichiro Hasegawa, Hiroyuki Ishida, Nao Yoshida, Takashi Koike, Yoshiyuki Takahashi, Katsuyoshi Koh, Yasuhiro Okamoto, Hideki Sano, Keisuke Kato, Yoshinobu Kanda, Hiroaki Goto, Junko Takita, Takako Miyamura, Maiko Noguchi, Koji Kato, Yoshiko Hashii, Yoshiko Astuta, Hiromasa Yabe .  Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis. .  International journal of hematology113 ( 1 ) 134 - 144   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We retrospectively analyzed nationwide records of 163 Fanconi anemia (FA) patients [aplastic anemia (AA), n = 118; myelodysplastic syndrome (MDS), n = 30; acute leukemia, n = 15] who underwent first allogeneic hematopoietic stem cell transplantation (HSCT) between 1987 and 2015 in Japan. An alternative donor was used in 119 (73%) patients, and 160 (98%) patients received a non-T-cell-depleted graft. With an 8.7-year median follow-up, 5-year overall survival (OS) was 81%. The 5-year OS was significantly higher in AA patients than in MDS and acute leukemia patients (89%, 71%, and 44%, respectively). In the MDS/leukemia group, factors associated with poor outcome in univariate analysis were older age at HSCT (≥ 18 years), conditioning regimen without anti-thymocyte or lymphocyte globulin, and grade II-IV acute graft-versus-host disease. After 1 year, of 137 survivors, 15 developed subsequent malignancies, of whom 12 were diagnosed with head and neck (HN)/esophageal cancer. An irradiation regimen and older age were associated with the risk of HN/esophageal cancer. Five of seven deaths were attributed to subsequent malignancies more than 5 years after HSCT. On the basis of the risk factors for HSCT in MDS/leukemia patients and subsequent malignancies, a more effective HSCT approach is required.

    DOI: 10.1007/s12185-020-02991-x

    Scopus

    PubMed

  • Yabe Miharu, Morio Tomohiro, Tabuchi Ken, Tomizawa Daisuke, Hasegawa Daiichiro, Ishida Hiroyuki, Yoshida Nao, Koike Takashi, Takahashi Yoshiyuki, Koh Katsuyoshi, Okamoto Yasuhiro, Sano Hideki, Kato Keisuke, Kanda Yoshinobu, Goto Hiroaki, Takita Junko, Miyamura Takako, Noguchi Maiko, Kato Koji, Hashii Yoshiko, Atsuta Yoshiko, Yabe Hiromasa .  Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis(和訳中) .  International Journal of Hematology113 ( 1 ) 134 - 144   2021.1Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis(和訳中)

     More details

    Language:English   Publisher:(一社)日本血液学会  

    同種造血幹細胞移植(HSCT)はFanconi貧血(FA)患者の血液疾患に対する唯一の治癒的治療法である。1987〜2015年に初めてHSCTを施行されたFA患者163例(再生不良性貧血(AA)118例、骨髄異形成症候群(MDS)30例、急性白血病15例)の全国記録を後方視的に解析した。患者119例が代替ドナーのグラフトを使用し、160例が非T細胞除去グラフトを受けた。追跡期間中央値8.7年で、5年全生存率は81%であった。AA患者の5年全生存率は、MDSおよび急性白血病患者よりも有意に高かった(それぞれ89%、71%、44%)。MDS/白血病群では、単変量解析による転帰不良の要因として、造血幹細胞移植時の年齢が高いこと(18歳以上)、抗胸腺細胞または抗リンパ球グロブリンを使用しない移植前処置、グレードII〜IVの急性移植片対宿主病が挙げられた。1年後、生存者137例のうち、15例が悪性腫瘍を発症し、12例を頭頸部/食道癌と診断した。頭頸部/食道癌のリスクには、照射レジメンと高齢が関連していた。死亡者7例のうち5例は、造血幹細胞移植後5年以上経過してから発生した悪性腫瘍が原因であった。MDS/白血病患者における造血幹細胞移植のリスク因子とその後の悪性腫瘍に基づいて、より効果的な造血幹細胞移植のアプローチが必要と考えられた。

  • Hirotoshi Sakaguchi, Takako Miyamura, Daisuke Tomizawa, Takashi Taga, Hiroyuki Ishida, Yasuhiro Okamoto, Katsuyoshi Koh, Tomoko Yokosuka, Nao Yoshida, Maho Sato, Maiko Noguchi, Keiko Okada, Tsukasa Hori, Masanobu Takeuchi, Yoshiyuki Kosaka, Masami Inoue, Yoshiko Hashii, Yoshiko Atsuta .  Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study. .  Bone marrow transplantation56 ( 8 ) 1859 - 1865   2021International journal

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Children with acute myeloid leukemia (AML) commonly develop extramedullary disease (EMD), which comprises central nervous system (CNS) lesions and myeloid sarcoma (MS). In this retrospective analysis, we aimed to determine the effect of EMD on the outcomes of allogeneic hematopoietic cell transplantation (HCT) in 678 pediatric patients with de novo AML (median age, 7 years; range, 0.3-15 years) between 2006 and 2016. We compared the outcomes between patients with (EMD group, n = 158; CNS lesion, n = 47, CNS lesion + MS, n = 9, and MS, n = 102) and without EMD at diagnosis (non-EMD group, n = 520). Survivors were followed for a median of 4.5 years, and the 4-year overall survival (OS) rates were 60.6% and 56.4% in the EMD and non-EMD groups, respectively (P = 0.60). No significant differences in OS were observed with respect to the EMD site, except bone lesions, which were associated with poor OS after HCT in a non-remission status. A multivariate analysis revealed that EMD did not affect the outcomes of HCT. In conclusion, the study findings suggest that EMD should not be considered a poor prognostic factor in HCT for children with AML.

    DOI: 10.1038/s41409-021-01250-9

    Scopus

    PubMed

  • Abematsu T. .  Successful Salvage of Very Early Relapse in Pediatric Acute Lymphoblastic Leukemia with Inotuzumab Ozogamicin and HLA-haploidentical Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide .  Journal of Pediatric Hematology/Oncology   2021

     More details

    Publisher:Journal of Pediatric Hematology/Oncology  

    DOI: 10.1097/MPH.0000000000002079

    Scopus

    PubMed

  • Shimomura Ikushi, Nakagawa Shunsuke, Abematsu Takanari, Hazeki Daisuke, Kodama Yuichi, Nishikawa Takuro, Okamoto Yasuhiro, Kawano Yoshifumi .  Successful treatment with extracorporeal circulation and chemotherapy for neuroblastoma complicated by cardiac shock and severe renal failure .  The Japanese Journal of Pediatric Hematology / Oncology58 ( 2 ) 166 - 170   2021

     More details

    Language:Japanese   Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    <p>A 2-year-old female presented with acute heart failure and renal failure, and she was started on Extra-corporeal membrane oxygenation (ECMO) and continuous hemodiafiltration (CHDF). ECMO led to improvement in her heart function; however, she developed high blood pressure following ECMO withdrawal. Computed tomography revealed a left adrenal tumor and double renal arteries that were narrowed at their origin. Urinary vanillylmandelic acid and homovanillic acid, as well as serum neuron-specific enolase levels were increased, and I<sup>123</sup>-metaiodobenzylguanidine (I<sup>123</sup>-MIBG) scintigraphy revealed I<sup>123</sup>-MIBG accumulation in the tumor. Blood tests showed high plasma renin and aldosterone levels. Bone marrow aspiration revealed abnormal cells, and she was diagnosed as having neuroblastoma and renovascular hypertension. We concluded that a neuroblastoma concomitant with renovascular hypertension precipitated hypertensive cardiac shock and severe renal failure. Chemotherapy improved hypertension and renal failure. Chemotherapy with ECMO and CHDF are effective rescue strategies in patients with neuroblastoma complicated by severe heart and renal failure.</p>

    DOI: 10.11412/jspho.58.166

  • Kawamura Junpei, Ueno Kentaro, Takumi Koji, Yoshiura Takashi, Okamoto Yasuhiro .  Four-Dimensional Flow Magnetic Resonance Imaging in the Evaluation of Intracardiac Oxygenation in an Infant With a Single Ventricle .  Circulation Journal   2021

     More details

    Language:English   Publisher:一般社団法人 日本循環器学会  

    DOI: 10.1253/circj.CJ-21-0551

    PubMed

  • MORIYAMA Mizuki, NISHIKAWA Takuro, NAKAMURA Tatsuro, ABEMATSU Takanari, NAKAGAWA Shunsuke, KODAMA Yuichi, OKAMOTO Yasuhiro, IWAMOTO Jiro, KAWANO Yoshifumi .  Improvement in platelet count and bleeding symptom during treatment with eltrombopag in a patient with X-linked thrombocytopenia .  Rinsho Ketsueki62 ( 4 ) 257 - 261   2021

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Japanese Society of Hematology  

    <p>Herein, we describe a 13-year-old male adolescent who had chronic thrombocytopenia since infancy. In this case, X-linked thrombocytopenia (XLT) was suspected owing to a family history of chronic thrombocytopenia and small-sized platelets. Moreover, the patient was refractory to immunoglobulin therapy. The Wiskott-Aldrich syndrome protein (WASP) expression analysis revealed a decreased expression. Results showed a missense mutation [c.296A>G (p.Gln99Arg)] in exon 3 of the WASP-interacting protein region. Therefore, a diagnosis of XLT was made. To lift exercise restrictions, we initiated treatment with eltrombopag at a dose of 12.5 mg/day. The platelet count of the patient increased to approximately 50×10<sup>3</sup>/µ<i>l</i> after the treatment dose was escalated to 25 mg/day, and bleeding symptoms decreased after the patient resumed exercise. Ultrastructural platelet abnormalities and abnormal platelet aggregation were observed on transmission electron microscopy after the administration of eltrombopag. Therefore, eltrombopag treatment can increase platelet count and reduce bleeding symptoms in patients with XLT.</p>

    DOI: 10.11406/rinketsu.62.257

    PubMed

  • Shunichiro Toya, Migita Masahiro, Kohrogi Kensaku, Funakoshi Yasutomo, Suenobu Souichi, Saitoh Yusuke, Shinkoda Yuichi, Higa Takashi, Hyakuna Nobuyuki, Karakawa Shuhei, Takemoto Junkichi, Koga Yuhki, Ohga Shouichi, Okamoto Yasuhiro, Nomura Yuko, Nakayama Hideki, Ozono Shuichi, Honda Yuko, Kohroki Masahiko, Nishi Masanori .  Current status of pediatric cancer treatment during the COVID-19 pandemic:—A questionnaire survey of childhood cancer cooperation in hospitals in Kyushu-Okinawa Area— .  The Japanese Journal of Pediatric Hematology / Oncology58 ( 2 ) 132 - 137   2021

     More details

    Language:Japanese   Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    <p>Background: The COVID-19 pandemic, which began in 2020, has dragged on and changed people's lifestyles. Pediatric cancer patients are receiving chemotherapy while taking adequate measures against COVID-19 infection.</p><p>Methods: At Kyushu-Okinawa area pediatric cancer hospitals, in June 2020 (after the first wave of COVID-19 infections in Japan) and September 2020 (after the second wave), we investigated the (1) experience with COVID-19, (2) its impact on medical care, and (3) its social and mental impact on patients and healthcare professionals. We discussed these issues at the monthly WEB conference.</p><p>Results: There were no cases of COVID-19 infection among pediatric cancer patients. The present situation had no effects on the outcomes of patients who were forced to change treatment for their underlying diseases. Visits and overnight stays of family caregivers, parent meetings, volunteer activities, nursery teachers/child life specialists, and playroom/in-hospital school management were restricted at all hospitals. Many patients and families suffered mental stress. The number of outpatients decreased. Telemedicine was provided at six facilities. Some restrictions were relaxed between the first and second waves, and the number of outpatients is now returning to normal.</p><p>Conclusion: COVID-19 rarely becomes severe in children. However, there are concerns about the effects of treatment changes and interruptions in care for hematological malignancies. These patients need not only adequate infection control but also mental care.</p>

    DOI: 10.11412/jspho.58.132

  • Yasuhiro Okamoto, Yozo Nakazawa, Masami Inoue, Kenichiro Watanabe, Hiroaki Goto, Nao Yoshida, Maiko Noguchi, Atsushi Kikuta, Koji Kato, Yoshiko Hashii, Yoshiko Atsuta, Motohiro Kato .  Hematopoietic stem cell transplantation in children and adolescents with nonremission acute lymphoblastic leukemia. .  Pediatric blood & cancer67 ( 12 ) e28732   2020.12International journal

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The appropriateness of allogeneic hematopoietic stem cell transplantation (HSCT) in children and adolescents with leukemia in whom complete remission is not possible remains unclear. This retrospective analysis aimed to investigate the outcomes associated with HSCT, and the risks of HSCT in children and adolescents with nonremission acute lymphoblastic leukemia (ALL). PROCEDURE: Data from the Japan Society for Hematopoietic Cell Transplantation registry on 325 patients with nonremission ALL (aged <21 years, with blasts in the peripheral blood and/or bone marrow) who had undergone HSCT between January 2001 and December 2015 were evaluated. To assess survival, we developed a scoring system using significant adverse pre-HSCT variables. RESULTS: Overall, 247 patients died. The median length of follow up among survivors was 1145 days, and the 3-year overall survival was 22% (95% confidence interval [CI]: 18-27%). A low performance score, presence of >25% bone marrow blasts, T-cell phenotype, poor-risk or normal cytogenetics, and history of HSCT were predictors of a poor outcome. Patients scoring 0-1 (n = 109), 2 (n = 91), and 3-7 (n = 125) had a 3-year overall survival of 41% (95% CI: 31-51%), 21% (95% CI: 13-31%), and 7% (95% CI: 3-12%), respectively. CONCLUSION: These results support HSCT in certain nonremission patients. Even in patients without complete remission, outcomes differed according to pre-HSCT factors. A scoring system could help determine the appropriateness of HSCT in children and adolescents with nonremission ALL.

    DOI: 10.1002/pbc.28732

    Scopus

    PubMed

  • 杉田 光士郎, 川野 孝文, 山田 耕嗣, 山田 和歌, 児玉 祐一, 西川 拓朗, 岡本 康裕, 加治 建, 河野 嘉文, 家入 里志 .  仙尾部胚細胞腫瘍15例の診療経験による臨床的検討 .  日本小児血液・がん学会雑誌57 ( 4 ) 322 - 322   2020.10仙尾部胚細胞腫瘍15例の診療経験による臨床的検討

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

  • 長野 綾香, 春松 敏夫, 武藤 充, 山田 耕嗣, 松久保 眞, 西川 拓朗, 岡本 康裕, 加治 建, 河野 嘉文, 家入 里志 .  腹腔鏡手術により摘出した副腎VIP分泌性神経芽腫の1例 .  日本小児血液・がん学会雑誌57 ( 2 ) 190 - 190   2020.9腹腔鏡手術により摘出した副腎VIP分泌性神経芽腫の1例

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

  • Shohei Nakajima, Iori Sato, Takafumi Soejima, Katsuyoshi Koh, Motohiro Kato, Yasuhiro Okamoto, Toshihiko Imamura, Miho Maeda, Yasushi Ishida, Atsushi Manabe, Kiyoko Kamibeppu .  Comparison of child and family reports of health-related quality of life in pediatric acute lymphoblastic leukemia patients after induction therapy. .  BMC pediatrics20 ( 1 ) 390 - 390   2020.8International journal

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: This study aims at determining the health-related quality of life (HRQOL) of children with acute lymphoblastic leukemia (ALL) after the induction therapy, assessing the agreement between child self-reports and family proxy-reports HRQOL, and determining the factors related to this agreement, especially child age, family attendance, and children's social relationships beyond the family. METHODS: We analyzed questionnaire data (2012-2017) from the Japanese Pediatric Leukemia/Lymphoma Study Group's clinical study (ALL-B12). Participants were children with B-cell precursor ALL aged 5-18 and their family members, who mostly took care of the child during hospitalization. Participants answered the Pediatric Quality of Life Inventory™ (PedsQL™) Generic Core Scales (PedsQL-G), and Cancer Module (PedsQL-C) to measure pediatric HRQOL. We calculated the differences between child self-reported and family proxy-reported subscale scores along with intraclass correlation coefficients (ICC). We conducted multiple regression analyses according to all participant pairs and age groups (young children, school age, and adolescents), with ICCs for all PedsQL-G subscales (ICC-G) and all PedsQL-C subscales (ICC-C) as the outcome variables. RESULTS: Five hundred twenty-two pairs of children and their families were analyzed. We observed a moderate level of agreement on most PedsQL subscales between child self-reports and family proxy-reports; however, worry had the weakest agreement for all PedsQL subscales (ICC = .32, 95% confidence interval = .24-.40). The agreement of ICC-C was positively related to family attendance in the hospitalization, only for the young children group (B = .185, p = .003). CONCLUSIONS: We observed some differences between child self-reports and family proxy-reports of HRQOL of children with ALL. Both child self-reports and family proxy-reports captured HRQOL in the induction therapy. We suggest that attending to young children's hospitalization affects the level of agreement between reports on their HRQOL.

    DOI: 10.1186/s12887-020-02287-3

    Scopus

    PubMed

  • 中川 俊輔, 岡本 康裕, 櫨木 大祐, 児玉 祐一, 西川 拓朗, 江口 太助, 林 完勇, 河野 嘉文 .  経鼻胃管によって異所性右鎖骨下動脈-食道瘻を来したびまん性橋膠腫(Diffuse intrinsic pontine glioma with aberrant right subclavian artery-esophageal fistula induced by nasogastric tube) .  日本小児血液・がん学会雑誌57 ( 1 ) 20 - 23   2020.6経鼻胃管によって異所性右鎖骨下動脈-食道瘻を来したびまん性橋膠腫(Diffuse intrinsic pontine glioma with aberrant right subclavian artery-esophageal fistula induced by nasogastric tube)

     More details

    Publisher:(一社)日本小児血液・がん学会  

    異所性右鎖骨下動脈-食道瘻は稀だが,止血が困難で,致死的な疾患である.症例は4歳のびまん性橋膠腫の患児で,放射線治療と化学療法中に突然大量に吐血し,出血性ショックを来した.上部消化管内視鏡検査で経鼻胃管による食道潰瘍から出血を認めた.食道バルーンで応急的に止血し,造影CTで異所性右鎖骨下動脈-食道瘻を確認した.その後,経カテーテル的動脈塞栓術で完全に止血でき,救命できた.本症例は,小児がん患者が異所性右鎖骨下動脈-食道瘻を発症した点と,経カテーテル的動脈塞栓術で止血に成功した点のいずれにおいても最初の報告である.化学療法は粘膜障害を引き起こすため,胃管留置による潰瘍や瘻孔形成を増悪させる可能性がある.胃管を留置して化学療法を行う前には異所性右鎖骨下動脈の有無を評価する必要がある.経カテーテル的動脈塞栓術は異所性右鎖骨下動脈-食道瘻に対して有効な止血手段である.(著者抄録)

  • Japan Children's Cancer Group: International collaborations and plans .      2020.5Japan Children's Cancer Group: International collaborations and plansInvited Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • 竹元 將人, 丸山 慎介, 宮園 明典, 塩川 直宏, 中川 俊輔, 岡本 康裕, 井手迫 俊彦, 河野 嘉文 .  後部尿道弁でピボキシル基含有抗菌薬の排泄が遅延しC5上昇が持続した1例 .  日本マス・スクリーニング学会誌30 ( 1 ) 43 - 49   2020.5後部尿道弁でピボキシル基含有抗菌薬の排泄が遅延しC5上昇が持続した1例

     More details

    Publisher:日本マススクリーニング学会  

    イソ吉草酸血症は新生児マススクリーニングの対象疾患である。イソバレリルカルニチン(C5)を指標に検査が行われているが、ピボキシル基含有抗菌薬を使用すると偽陽性例が発生することが知られている。後部尿道弁は男児の器質的下部尿路通過障害を引き起こす先天性異常である。今回、新生児マススクリーニングでのC5上昇からイソ吉草酸血症を疑われたが、後部尿道弁と診断した1症例を経験した。症例は日齢18の男児。産院を退院後、腹部膨満と哺乳量減少が出現。新生児マススクリーニング異常の精査目的に受診した際に、活気不良および高度の脱水のため入院した。高度のアシドーシスも認め、イソ吉草酸血症の急性発症を疑ったが、アニオンギャップは正常で、高糖濃度輸液とL-カルニチン投与では全身状態とアシドーシスが改善しなかった。腹部超音波検査で両側水腎症を認め、排尿時膀胱造影で後部尿道弁と診断した。アシドーシスは閉塞性尿路障害で生じた続発性偽性低アルドステロン症による腎尿細管性アシドーシスIV型と診断した。尿道カテーテル留置による排尿によってアシドーシスと腎機能障害は改善し、C5も正常化した。新生児マススクリーニング陽性例の鑑別において代謝性アシドーシスの評価は重要であった。C5上昇は後部尿道弁に伴う腎後性腎不全により出生直後に投与されたピボキシル基含有抗菌薬の排泄が遅延したことが原因と考えられた。(著者抄録)

  • 竹元 將人, 丸山 慎介, 宮園 明典, 塩川 直宏, 中川 俊輔, 岡本 康裕, 井手迫 俊彦, 河野 嘉文 .  後部尿道弁でピボキシル基含有抗菌薬の排泄が遅延しC5上昇が持続した1例 .  日本マス・スクリーニング学会誌30 ( 1 ) 43 - 49   2020.5

     More details

    Language:Japanese   Publisher:日本マススクリーニング学会  

    イソ吉草酸血症は新生児マススクリーニングの対象疾患である。イソバレリルカルニチン(C5)を指標に検査が行われているが、ピボキシル基含有抗菌薬を使用すると偽陽性例が発生することが知られている。後部尿道弁は男児の器質的下部尿路通過障害を引き起こす先天性異常である。今回、新生児マススクリーニングでのC5上昇からイソ吉草酸血症を疑われたが、後部尿道弁と診断した1症例を経験した。症例は日齢18の男児。産院を退院後、腹部膨満と哺乳量減少が出現。新生児マススクリーニング異常の精査目的に受診した際に、活気不良および高度の脱水のため入院した。高度のアシドーシスも認め、イソ吉草酸血症の急性発症を疑ったが、アニオンギャップは正常で、高糖濃度輸液とL-カルニチン投与では全身状態とアシドーシスが改善しなかった。腹部超音波検査で両側水腎症を認め、排尿時膀胱造影で後部尿道弁と診断した。アシドーシスは閉塞性尿路障害で生じた続発性偽性低アルドステロン症による腎尿細管性アシドーシスIV型と診断した。尿道カテーテル留置による排尿によってアシドーシスと腎機能障害は改善し、C5も正常化した。新生児マススクリーニング陽性例の鑑別において代謝性アシドーシスの評価は重要であった。C5上昇は後部尿道弁に伴う腎後性腎不全により出生直後に投与されたピボキシル基含有抗菌薬の排泄が遅延したことが原因と考えられた。(著者抄録)

  • 池田 正樹, 西川 拓朗, あべ松 貴成, 川村 順平, 横山 智美, 平井 克樹, 宮原 恵弥子, 茂見 茜里, 猪川 和朗, 岡本 康裕, 右田 昌宏, 河野 嘉文 .  自家末梢血幹細胞移植後に肺動脈性肺高血圧と移植関連血栓性微小血管症を発症した神経芽腫患児 .  日本造血細胞移植学会雑誌9 ( 2 ) 60 - 64   2020.4自家末梢血幹細胞移植後に肺動脈性肺高血圧と移植関連血栓性微小血管症を発症した神経芽腫患児

     More details

    Publisher:(一社)日本造血細胞移植学会  

    症例は左上縦隔原発、骨転移の神経芽腫の2歳女児。化学療法後にbusulfan、melphalanを用いた大量化学療法を行い、自家末梢血幹細胞移植を施行した。day 61に易疲労感、低酸素血症を主訴として肺高血圧症を発症した。Day 91には貧血、破砕赤血球の出現、血小板減少、血清クレアチニン上昇があり、移植関連血栓性微小血管症(TA-TMA)と診断した。肺高血圧症も悪化がみられ、心臓カテーテル検査で肺動脈性肺高血圧(PAH)と診断した。水分管理でTA-TMAは改善し、PAHは酸素療法で治療開始した。day 131に肺高血圧クライシスから心停止を来した。集学的治療により救命し得たが、神経学的後遺症を残した。PAHは、sildenafil、bosentanを開始し、改善した。PAH、TA-TMAはいずれも血管内皮障害に起因する造血幹細胞移植後の重篤な合併症であり、移植後にPAHを発症した症例においてはTMAの所見が出ないか注意してフォローアップする必要がある。(著者抄録)

  • Kawabata T, Tenokuchi Y, Yamakuchi H, Sameshima H, Katayama H, Ota T, Tokunaga M, Takezaki T, Tamae S, Nakamura T, Chang B, Kodama Y, Imuta N, Ooka T, Okamoto Y, Suga S, Nishi J .  Concurrent Bacteremia Due to Non-vaccine Serotype 24F Pneumococcus in Twins: A Rapid Increase in Serotype 24F-invasive Pneumococcal Disease and its High Invasive Potential. .  Pediatr Infect Dis J   2020.1Concurrent Bacteremia Due to Non-vaccine Serotype 24F Pneumococcus in Twins: A Rapid Increase in Serotype 24F-invasive Pneumococcal Disease and its High Invasive Potential.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Kawabata T. .  Concurrent Bacteremia Due to Non-vaccine Serotype 24F Pneumococcus in Twins: A Rapid Increase in Serotype 24F-invasive Pneumococcal Disease and its High Invasive Potential .  The Pediatric infectious disease journal39 ( 1 ) 85 - 87   2020.1

     More details

    Publisher:The Pediatric infectious disease journal  

    DOI: 10.1097/INF.0000000000002508

    Scopus

    PubMed

  • Nakagawa Shunsuke, Okamoto Yasuhiro, Hazeki Daisuke, Kodama Yuichi, Nishikawa Takuro, Eguchi Taisuke, Hayashi Sadao, Kawano Yoshifumi .  Diffuse intrinsic pontine glioma with aberrant right subclavian artery–esophageal fistula induced by nasogastric tube .  The Japanese Journal of Pediatric Hematology / Oncology57 ( 1 ) 20 - 23   2020

     More details

    Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    <p>An aberrant right subclavian artery (ARSA)–esophageal fistula is rare but highly fatal. A 4-year-old female patient with diffuse intrinsic pontine glioma presented with sudden massive hematemesis. Upper gastrointestinal endoscopy revealed massive pulsing bleeding from an ulcer in contact with a nasogastric tube (NGT) in the upper esophagus. A balloon in the esophagus stopped the bleeding temporally, and computed tomography revealed an ARSA–esophageal fistula. Transarterial embolization (TAE) stopped the bleeding completely, and she was saved. This is the first case of a pediatric cancer patient of its kind. Mucosal damage induced by chemotherapy might contribute to fistular development. Furthermore, this is the first report of a successful rescue of a patient with an ARSA–esophageal fistula by TAE. Therefore, we suggest evaluating the existence of ARSA in pediatric cancer patients with NGT insertion and treated with chemotherapy. TAE is effective in stopping the bleeding from an ARSA–esophageal fistula.</p>

    DOI: 10.11412/jspho.57.20

  • Nao Yoshida, Yoshiyuki Takahashi, Hiromasa Yabe, Ryoji Kobayashi, Kenichiro Watanabe, Kazuko Kudo, Miharu Yabe, Takako Miyamura, Katsuyoshi Koh, Hiroshi Kawaguchi, Hiroaki Goto, Naoto Fujita, Keiko Okada, Yasuhiro Okamoto, Koji Kato, Masami Inoue, Ritsuro Suzuki, Yoshiko Atsuta, Seiji Kojima .  Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide. .  Bone marrow transplantation55 ( 7 ) 1272 - 1281   2020International journal

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Fludarabine/cyclophosphamide-based conditioning regimens are standard in bone marrow transplantation (BMT) for acquired bone marrow failure in children, however, graft failure may occur. Using the data from a nationwide transplantation registry, we compared the outcomes of children aged <16 years with acquired aplastic anemia and refractory cytopenia of childhood who underwent allogeneic BMT with either fludarabine/melphalan (n = 71) or fludarabine/cyclophosphamide (n = 296) between 2000 and 2016. The fludarabine/melphalan regimen provided excellent outcomes, with 3-year overall survival and failure-free survival rates of 98% and 97%, respectively. The 83% 3-year failure-free survival in the fludarabine/cyclophosphamide group was significantly inferior (P = 0.002), whereas the overall survival did not differ between the two groups. Late graft failure was the most common cause of treatment failure in the fludarabine/cyclophosphamide group, which experienced a significantly higher incidence of late graft failure than the fludarabine/melphalan group (11% vs. 3%; P = 0.035). Multivariate analyses showed that the fludarabine/melphalan regimen was associated with a better failure-free survival (hazard ratio [HR] 0.12; P = 0.005) and lower risk of late graft failure (HR 0.16; P = 0.037). Fludarabine/melphalan-based conditioning regimen can be a promising option for children with acquired bone marrow failure receiving BMT.

    DOI: 10.1038/s41409-020-0948-8

    Scopus

    PubMed

  • Ikeda Masaki, Okamoto Yasuhiro, Migita Masahiro, Kawano Yoshifumi, Nishikawa Takuro, Abematsu Takanari, Kawamura Junpei, Yokoyama Satomi, Hirai Katsuki, Miyahara Emiko, Shigemi Akari, Ikawa Kazuro .  Pulmonary arterial hypertension and transplant-associated thrombotic microangiopathy in a child with neuroblastoma after autologous peripheral blood stem cell transplantation .  Journal of Hematopoietic Cell Transplantation9 ( 2 ) 60 - 64   2020

     More details

    Publisher:The Japan Society for Hematopoietic Stem Cell Transplantation  

    <p> We describe the case of a 2-year-old girl with a primary left upper mediastinal neuroblastoma with bone metastasis. She underwent autologous peripheral blood stem cell transplantation following chemotherapy with high-dose busulfan-melphalan. On day 61, she developed pulmonary hypertension with generalized fatigue and hypoxemia. On day 91, she was diagnosed with transplant-associated thrombotic microangiopathy (TA-TMA) secondary to anemia, red cell fragmentation, thrombocytopenia, and elevated serum creatinine levels, and her pulmonary hypertension worsened. She underwent cardiac catheterization and was diagnosed with pulmonary arterial hypertension (PAH). Management of fluid balance led to improvement in TA-TMA, and oxygen therapy was initiated for PAH. On day 131, she developed cardiac arrest secondary to pulmonary hypertensive crisis. Although she was successfully treated with multidisciplinary therapy, she had neurological sequelae. PAH improved following treatment with sildenafil and bosentan. PAH and TA-TMA are serious complications that may occur owing to vascular endothelial damage after hematopoietic stem cell transplantation. Clinicians must be vigilant for TA-TMA in patients who develop PAH after hematopoietic stem cell transplantation.</p>

    DOI: 10.7889/hct-19-009

  • Miyamura T, Kudo K, Tabuchi K, Ishida H, Tomizawa D, Adachi S, Goto H, Yoshida N, Inoue M, Koh K, Sasahara Y, Fujita N, Kakuda H, Noguchi M, Hiwatari M, Hashii Y, Kato K, Atsuta Y, Okamoto Y .  Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan. .  Leukemia research87   106263 - 106263   2019.12Reviewed International journal

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Pediatric acute myeloid leukemia (AML) with KMT2A rearrangement is detected in 15-20% of all pediatric AML patients and is associated with adverse outcomes even after allogeneic hematopoietic stem cell transplantation (HSCT). To investigate outcomes and prognostic factors, we investigated 90 pediatric AML patients with KMT2A rearrangement after allogeneic HSCT. METHODS: We retrospectively analyzed Japanese registration data for patients who had received allogeneic HSCT between 1988 and 2011. Median age was 3 years (range, 0-15 years), and no gender difference was evident. Median observation period was 119 months. RESULTS: The 3-year overall survival (OS) rate of KMT2A-rearranged AML was 52.1% (95% confidence interval (CI), 42.4-64%, n = 90), and the 3-year disease-free survival (DFS) rate was 46.7% (95%CI, 36.8-58.2%). The 3-year DFS of KMT2A-rearranged AML was not significantly poorer than that of other AML (P = 0.09), and no significant difference was also seen in 3-year OS rate (P = 0.21). Multivariate analysis showed disease status (complete remission) at HSCT was associated with better outcomes. A significant difference in treatment-related mortality (TRM) was apparent between HSCT from a HLA full-matched related donor and that from a haploidentical donor (P = 0.001). DISCUSSION: HSCT is a curative option for pediatric AML with KMT2A rearrangement. Pretransplant status was the most significant prognostic indicator for relapse and survival. Enhancing supportive therapy to reduce TRM will further improve treatment outcomes of KMT2A-rearranged pediatric AML.

    DOI: 10.1016/j.leukres.2019.106263

    Scopus

    PubMed

  • Toshinobu Imashioya, Yuichi Kodama, Tadasuke Ooka, Shunsuke Nakagawa, Takuro Nishikawa, Takayuki Tanabe, Yasuhiro Okamoto, Naoko Imuta, Mari Kirishima, Akihide Tanimoto, Toyoyasu Koriyama, Junichiro Nishi, Yoshifumi Kawano .  Liver abscess due to Sterigmatomyces halophilus in a boy with acute lymphoblastic leukemia. .  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy25 ( 12 ) 1047 - 1049   2019.12Reviewed International journal

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We report the first case of liver abscess due to Sterigmatomyces halophilus. Because this pathogen grows poorly in culture medium without added salts, it was identified by sequencing analysis targeting the rRNA gene internal transcribed spacer (ITS) region. This method could be useful for pathogens that cannot be cultured using standard methods.

    DOI: 10.1016/j.jiac.2019.05.021

    Scopus

    PubMed

  • Imashioya Toshinobu, Kodama Yuichi, Ooka Tadasuke, Nakagawa Shunsuke, Nishikawa Takuro, Tanabe Takayuki, Okamoto Yasuhiro, Imuta Naoko, Kirishima Mari, Tanimoto Akihide, Koriyama Toyoyasu, Nishi Junichiro, Kawano Yoshifumi .  急性リンパ性白血病の小児におけるSterigmatomyces halophilusによる肝膿瘍(Liver abscess due to Sterigmatomyces halophilus in a boy with acute lymphoblastic leukemia) .  Journal of Infection and Chemotherapy25 ( 11-12 ) 1047 - 1049   2019.12急性リンパ性白血病の小児におけるSterigmatomyces halophilusによる肝膿瘍(Liver abscess due to Sterigmatomyces halophilus in a boy with acute lymphoblastic leukemia)

     More details

    Publisher:エルゼビア・ジャパン(株)  

    6歳男児。急性リンパ性白血病にて同種骨髄移植(allo-BMT)を予定していた。導入療法にて完全寛解が得られ、大量化学療法後に発熱性好中球減少症を発症した(day 0)。抗菌薬による治療を行ったが、発熱が続き、day 28に腹部CTで肝膿瘍がみられた。真菌による肝膿瘍を疑い、アムホテリシンBリポソーム製剤を投与したが、発熱が続いた。day 37に腹腔鏡下肝生検を行い、類上皮細胞肉芽腫および酵母様真菌を認めた。真菌rRNA遺伝子のITS領域のPCR増幅により単一DNAバンドが得られ、塩基配列はSterigmatomyces halophilus CBS4609株と100%一致した。イトラコナゾールおよびフルシトシンの併用療法によりday 100頃に解熱し、day 106の腹部CTでは肝膿瘍は認められなかった。day 150にきょうだいからallo-BMTを行ったところ、急性リンパ性白血病を再発した。化学療法と父親からの造血幹細胞移植にて寛解し、肝膿瘍の再発は認めなかった。

  • Ishimaru S, Okamoto Y, Imai C, Sakaguchi H, Taki T, Hasegawa D, Cho Y, Kakuda H, Sano H, Manabe A, Imamura T, Kato M, Arakawa Y, Shimonodan H, Sato A, Suenobu S, Inukai T, Watanabe A, Kawano Y, Kikuta A, Horibe K, Ohara A, Koh K. .  Nationwide Survey of Pediatric Hypodiploid Acute Lymphoblastic Leukemia in Japan. .  Pediatr Int   2019.11Nationwide Survey of Pediatric Hypodiploid Acute Lymphoblastic Leukemia in Japan.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Ishimaru S, Okamoto Y, Imai C, Sakaguchi H, Taki T, Hasegawa D, Cho Y, Kakuda H, Sano H, Manabe A, Imamura T, Kato M, Arakawa Y, Shimonodan H, Sato A, Suenobu S, Inukai T, Watanabe A, Kawano Y, Kikuta A, Horibe K, Ohara A, Koh K .  Nationwide Survey of Pediatric Hypodiploid Acute Lymphoblastic Leukemia in Japan. .  Pediatrics international : official journal of the Japan Pediatric Society61 ( 11 ) 1103 - 1108   2019.11Reviewed International journal

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Ploidy is a highly significant prognostic factor for pediatric acute lymphoblastic leukemia (ALL). Children with hypodiploid ALL have poor outcomes despite current intensive chemotherapy. Little has been investigated with regard to hypodiploid ALL in Japanese children. METHODS: We retrospectively collected clinical data on hypodiploid ALL cases from the registries of prospective multicenter trials conducted by the four independent clinical study groups in Japan between 1997 and 2012. RESULTS: A total of 117 ALL patients with hypodiploidy were analyzed in this study. There were 101, eight, and eight patients with 45, 44, and fewer than 44 chromosomes, respectively. The 5 year overall survival rates differed significantly: 86.0%, 87.5%, and 62.5% for patients with 45, 44, and fewer than 44 chromosomes, respectively (P = 0.037). Of the eight patients with 44 chromosomes, seven were alive, including five patients who maintained complete remission without undergoing hematopoietic stem cell transplantation (HSCT). Of the eight patients with fewer than 44 chromosomes, six were good responders to prednisolone and none had induction failure, but the relapse rate was high (5/8). No patients had central nervous system relapse. Four patients underwent HSCT after relapse, but only one survived. CONCLUSIONS: Outcomes of Japanese ALL patients with fewer than 44 chromosomes were poor, as previously reported in other countries. Although the sample size was small, patients with 44 chromosomes had better prognoses than those previously reported. Further studies including international collaboration are needed to improve outcomes for pediatric ALL patients with fewer than 44 chromosomes.

    DOI: 10.1111/ped.14006

    Scopus

    PubMed

  • Ishimaru Sae, Okamoto Yasuhiro, Imai Chihaya, Sakaguchi Hirotoshi, Taki Tomohiko, Hasegawa Daisuke, Cho Yuko, Kakuda Harumi, Sano Hideki, Manabe Atsushi, Imamura Toshihiko, Kato Motohiro, Arakawa Yuki, Shimonodan Hidemi, Sato Atsushi, Suenobu Souichi, Inukai Takeshi, Watanabe Arata, Kawano Yoshifumi, Kikuta Atsushi, Horibe Keizo, Ohara Akira, Koh Katsuyoshi .  日本における小児低二倍体急性リンパ芽球性白血病についての全国調査(Nationwide survey of pediatric hypodiploid acute lymphoblastic leukemia in Japan) .  Pediatrics International61 ( 11 ) 1103 - 1108   2019.11日本における小児低二倍体急性リンパ芽球性白血病についての全国調査(Nationwide survey of pediatric hypodiploid acute lymphoblastic leukemia in Japan)

     More details

    Publisher:John Wiley & Sons Australia, Ltd  

    日本における低二倍体を示す急性リンパ芽球性白血病(ALL)の小児患児について後ろ向き調査を行った。1997〜2012年の期間に日本で四つの研究グループが施行した前向き多施設共同試験の登録症例の臨床データを収集し、低二倍体ALL患児の症例117名を解析対象とした。染色体数が45本であった患児は101名、44本は8名、44本未満であったのは8名であり、この3集団の5年全生存率は同順で86.0%、87.5%、62.5%であって有意差が存在していた。染色体が44本であった8名中7名は生存しており、その生存例のうち5名は造血幹細胞移植を受けること無く完全寛解を維持していた。44本未満であった8名においては、6名でプレドニゾロンに対し良好な反応がみられ、寛解導入に失敗した例は無かったものの再発率は8名中5名と高かった。中枢神経再発をきたした患児はいなかった。4名では再発後に造血幹細胞移植が行われていたがそのうち生存例は1名のみであった。以前に他国で報告されていた通り、日本人のALL患児でも染色体数が44本未満の症例の予後は不良であった。本研究で解析した症例数は少ないものの、染色体数が44本の患児が示した予後は既報のものよりも良好であった。

  • Miyamura T, Kudo K, Tabuchi K, Ishida H, Tomizawa D, Adachi S, Goto H, Yoshida N8, Inoue M, Koh K, Sasahara Y, Fujita N, Kakuda H, Noguchi M, Hiwatari M, Hashii Y, Kato K, Atsuta Y, Okamoto Y .  Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan. .  Leuk Lymph   2019.10Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.leukres.2019.106263.

  • Imamura M, Okamoto Y, Nishikawa T, Yoneyama T, Yamasaki Y, Kawamura J, Kawano Y .  Celecoxib as a Potential Treatment for Intractable Lymphatic Malformation. .  Pediatrics   2019.9Celecoxib as a Potential Treatment for Intractable Lymphatic Malformation.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Yasuhiro Okamoto, Kazuko Kudo, Ken Tabuchi, Daisuke Tomizawa, Takashi Taga, Hiroaki Goto, Hiromasa Yabe, Yozo Nakazawa, Katsuyoshi Koh, Kazuhiro Ikegame, Nao Yoshida, Naoyuki Uchida, Kenichiro Watanabe, Yuuki Koga, Masami Inoue, Koji Kato, Yoshiko Atsuta, Hiroyuki Ishida .  Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. .  Bone marrow transplantation54 ( 9 ) 1489 - 1498   2019.9

     More details

    Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (median age: 13 years) patients 20 years or younger at HSCT, between January 2001 and December 2015, were included. A total of 314 patients died, and the median follow-up duration of the survivors was 1052 days. The most frequent cause of death was leukemia progression (58%). The 3-year overall survival (OS) rate was 23% (95% confidence interval [CI]: 19-28%). Chronic GVHD was associated with improved 3-year OS (47%, 95% CI, 36-57%, hazard ratio: 0.603, p = 0.001). Low performance status, presence of more than 25% of marrow blasts, presence of blasts in the blood at transplantation, FAB (other than M1 or M2), male donors, and number of transplantations ≥ 2 were adverse pre-HSCT variables. Patients with 0, 1-2, 3-4, 5, and 6-7 pre-HSCT variables had 3-year OS rates of 52%, 32%, 19%, 8, and 0%, respectively. Our findings may help experts decide if HSCT should be performed in such cases.

    DOI: 10.1038/s41409-019-0461-0

    Scopus

    PubMed

  • 井上 一利, 西川 拓朗, 平木 翼, 佐々木 裕美, 義岡 孝子, 中川 俊輔, 児玉 祐一, 岡本 康裕, 谷本 昭英, 河野 嘉文 .  診断に難渋した前腕原発spindle cell sarcomaの1例 .  日本小児血液・がん学会雑誌56 ( 2 ) 212 - 215   2019.9診断に難渋した前腕原発spindle cell sarcomaの1例

     More details

    Publisher:(一社)日本小児血液・がん学会  

    1歳9ヵ月の男児。左前腕部の腫脹に気付き紹介医を受診、MRI検査で6cm弱の充実性腫瘤を認め当科紹介となった。転移巣なく、生検術を行った。当初、生検材料の病理検索ではinfantile fibrosarcomaを考えたが、中央病理診断ではmyofibromaが疑われた。臨床的な判断に基づいて、vincristine、actinomycine、ifosfamideによる化学療法を開始したが、腫瘍径は変化なかった。中央病理診断の結果と治療反応から、化学療法は開始2ヵ月で中止した。中止3ヵ月後より腫瘤が増大し、中止4ヵ月後に腫瘍辺縁切除術を行った。この際の病理診断はspindle cell sarcoma、unclassifiedであった。局所照射、vincristine、ifosfamide、doxorubicinによる化学療法を3クール行い治療終了した。病理診断が臨床経過に合わない場合は、再度検体を採取し、病理検査を行うことを考慮する。(著者抄録)

  • 落合 佳代, 山田 愛, 木下 真理子, 澤 大介, 齋藤 祐介, 上村 幸代, 佐藤 勇一郎, 西川 拓朗, 岡本 康裕, 河野 嘉文, 川野 正人, 川野 孝文, 家入 里志, 盛武 浩 .  進行神経芽腫の再発との鑑別が困難であった限局性結節性過形成の2例 .  日本小児科学会雑誌123 ( 9 ) 1400 - 1405   2019.9進行神経芽腫の再発との鑑別が困難であった限局性結節性過形成の2例

     More details

    Publisher:(公社)日本小児科学会  

    症例1(5歳女児)。2歳時に神経芽腫(Stage IV)を発症し、造血幹細胞移植(HSCT)併用超大量化学療法を行った。だが、HSCT後2年6ヵ月後に頭蓋内腫瘍を認めたため開頭腫瘍全摘術を行い、神経芽腫再発の病理診断を得たが、全身検索で腹部MRIにて肝両葉の多発腫瘤が認められた。症例2(4歳男児)。1歳7ヵ月時に神経芽腫(Stage V)を発症し、HSCT併用超大量化学療法を施行したが、HSCT後2年2ヵ月の定期腹部超音波検査にて肝内多発腫瘤が認められた。いずれの症例も神経芽腫の再発を否定できず、腫瘍生検目的で肝部分切除術を施行し、FNH(限局性結節性過形成)と病理診断された。

  • 落合 佳代, 山田 愛, 木下 真理子, 澤 大介, 齋藤 祐介, 上村 幸代, 佐藤 勇一郎, 西川 拓朗, 岡本 康裕, 河野 嘉文, 川野 正人, 川野 孝文, 家入 里志, 盛武 浩 .  進行神経芽腫の再発との鑑別が困難であった限局性結節性過形成の2例 .  日本小児科学会雑誌123 ( 9 ) 1400 - 1405   2019.9

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    症例1(5歳女児)。2歳時に神経芽腫(Stage IV)を発症し、造血幹細胞移植(HSCT)併用超大量化学療法を行った。だが、HSCT後2年6ヵ月後に頭蓋内腫瘍を認めたため開頭腫瘍全摘術を行い、神経芽腫再発の病理診断を得たが、全身検索で腹部MRIにて肝両葉の多発腫瘤が認められた。症例2(4歳男児)。1歳7ヵ月時に神経芽腫(Stage V)を発症し、HSCT併用超大量化学療法を施行したが、HSCT後2年2ヵ月の定期腹部超音波検査にて肝内多発腫瘤が認められた。いずれの症例も神経芽腫の再発を否定できず、腫瘍生検目的で肝部分切除術を施行し、FNH(限局性結節性過形成)と病理診断された。

  • Seki Y, Okamoto Y, Kodama Y, Nishikawa T, Kawano Y .  Slowly Progressive Acute Lymphoblastic Leukemia after Stem Cell Transplantation .  Pediatr Int   2019.8Slowly Progressive Acute Lymphoblastic Leukemia after Stem Cell TransplantationReviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Seki Yuko, Okamoto Yasuhiro, Kodama Yuichi, Nishikawa Takuro, Kawano Yoshifumi .  幹細胞移植後の緩徐進行性急性リンパ性白血病(Slowly progressive acute lymphoblastic leukemia after stem cell transplantation) .  Pediatrics International61 ( 8 ) 831 - 832   2019.8幹細胞移植後の緩徐進行性急性リンパ性白血病(Slowly progressive acute lymphoblastic leukemia after stem cell transplantation)

     More details

    Publisher:John Wiley & Sons Australia, Ltd  

    症例は男児で、生後生後11ヵ月で前駆B急性リンパ性白血病と診断され、混合系統白血病(MLL)再配列を認めた。化学療法抵抗性であり、2回目の完全寛解後に幹細胞移植(HSCT)を実施した。ステージIの移植片対宿主病(GVHD)を発症したが、慢性GVHDは認めなかった。7年後、右精巣に単独再発したが切除に成功し、投薬なく通常の学校生活を送っていた。HSCTから13年後、左肘関節に間欠痛を認めた。血球数は正常の範囲内であった。2年後、疼痛が悪化し、MRIでは尺骨肘頭から尺骨骨幹域に異常信号を認めた。骨シンチグラフィーでは左肘関節に集積を認めた。3回目の再発が疑われたが、両側腸骨の骨髄検査の結果は陰性であった。HSCTから16年後、疼痛は左膝関節にまで拡大した。9ヵ月後に全身痛を呈し、検査値は貧血、血小板減少、乳酸脱水素酵素上昇を示した。骨髄検査ではMLL再配列を含めて初回診断時と同様の特徴がみられた。再導入療法後に疼痛は迅速に消失し、3ヵ月後のPET-CTでは著しい改善を認めた。同種間臍帯血を用いた2回目の移植を実施したが、肺合併症により5ヵ月後に死亡した。

  • 杉田 光士郎, 川野 孝文, 森口 智江, 大西 峻, 池江 隆正, 児玉 祐一, 西川 拓朗, 岡本 康裕, 加治 建, 家入 里志 .  異なる経過をたどった小児大腸癌の2例 .  日本小児外科学会雑誌55 ( 5 ) 968 - 976   2019.8異なる経過をたどった小児大腸癌の2例

     More details

    Publisher:(一社)日本小児外科学会  

    【症例1】14歳男児。主訴は食欲不振・るい痩で、腹部造影CT検査で腹部腫瘤を指摘され紹介となった。下行結腸に完全閉塞を伴う全周性隆起性病変とS状結腸以下に多発polypを認めた。左半結腸切除、D2+傍大動脈リンパ節郭清を行い、stage IVの診断であった。術後化学療法を行ったが、診断から1年後に死亡した。【症例2】10歳男児。主訴は血便・腹痛、腹部造影CT検査で腸重積の診断となり紹介となった。年齢と部位より器質的疾患の存在を考え、緊急で審査腹腔鏡を施行した。横行結腸脾彎曲部の腸重積部分に腫瘤性病変を認め、悪性リンパ腫と判断し局所切除を行った。病理診断は粘液癌で、腹腔鏡下左半結腸切除とD3リンパ節郭清を追加した。Stage IIIbの診断で化学療法を施行し、術後2年無再発生存中である。【結語】小児大腸癌は極めて稀であるが、年長時の遷延する消化器症状では鑑別する必要がある。(著者抄録)

  • Mitsunobu T, Nishikawa T, Kusuda M, Nakagawa S, Kodama Y, Okamoto Y, Kawano Y .  Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease. .  Journal of pediatric hematology/oncology42 ( 6 ) E456 - E458   2019.7

  • Nishikawa T, Yamaguchi H, Ikawa K, Nakayama K, Higashi E, Miyahara E, Abematsu T, Nakagawa S, Kodama Y, Tanabe T, Shigemi A, Shinkoda Y, Okamoto Y, Takeda Y, Kawano Y .  Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children. .  Pediatrics international : official journal of the Japan Pediatric Society61 ( 6 ) 558 - 565   2019.6

  • Nishikawa Takuro, Yamaguchi Hiroki, Ikawa Kazuro, Nakayama Kazutaka, Higashi Erika, Miyahara Emiko, Abematsu Takanari, Nakagawa Shunsuke, Kodama Yuichi, Tanabe Takayuki, Shigemi Akari, Shinkoda Yuichi, Okamoto Yasuhiro, Takeda Yasuo, Kawano Yoshifumi .  日本人小児のGST遺伝子多型がブスルファンの薬物動態に及ぼす影響(Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children) .  Pediatrics International61 ( 6 ) 558 - 565   2019.6日本人小児のGST遺伝子多型がブスルファンの薬物動態に及ぼす影響(Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children)

     More details

    Publisher:John Wiley & Sons Australia, Ltd  

    日本人小児患者のグルタチオンSトランスフェラーゼ(GST)遺伝子多型がブスルファンの薬物動態に及ぼす影響を評価し、ブスルファン曝露と毒性、遺伝子型と毒性の関連を分析した。ブスルファン静注による骨髄破壊的療法と造血幹細胞移植を施行された日本人小児20例(男児16例、女児4例、生後6ヵ月〜17歳)が試験に参加した。遺伝子型は17例が野生型(GSTA1*A/*A)、2例はヘテロ接合性バリアント(GSTA1*B/*B)、1例はヘテロ接合性バリアント(GSTA1*B/*B)であった。GSTA1、M1、T1はAUC0-∞、クリアランスまたは消失速度定数において有意差を認めなかった。予想外に高いAUC0-∞の幼児に対し、GSTA1、M1、T1遺伝子型は野生型であった。さらなる分析の結果、新陳代謝不良群は高代謝群と比較してクリアランスが低く、AUC0-∞が高いことが示された。以上から、GST遺伝子多型はブスルファンの薬物動態に影響する可能性があるが、これらの影響は基礎疾患、全身状態、治療歴、人種等の他の要因により不明確であった。

  • Yanagisawa R, Matsuda K, Ohga S, Kanegane H, Morimoto A, Okamoto Y, Ohara A, Fukushima K, Sotomatsu M, Nomura K, Saito AM, Horibe K, Ishii E, Nakazawa Y .  Correction to: Factors predicting the recurrence of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol. .  International journal of hematology109 ( 5 ) 629 - 629   2019.5Reviewed

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s12185-019-02641-x

    Scopus

    PubMed

    Other Link: http://link.springer.com/article/10.1007/s12185-019-02641-x/fulltext.html

  • 原尾 拓朗, 山田 愛, 木下 真理子, 澤 大介, 齋藤 祐介, 上村 幸代, 宮地 勇人, 荻野 尚, 児玉 祐一, 岡本 康裕, 河野 嘉文, 盛武 浩 .  KIT D816変異陽性全身性肥満細胞症から進展し化学療法終了後2ヵ月で再発した急性骨髄性白血病 .  臨床血液60 ( 5 ) 378 - 381   2019.5KIT D816変異陽性全身性肥満細胞症から進展し化学療法終了後2ヵ月で再発した急性骨髄性白血病

     More details

    Publisher:(一社)日本血液学会-東京事務局  

    症例は9歳女児。急性骨髄性白血病(AML)合併全身性肥満細胞症(SM-AML)を発症した。膀胱直腸障害を認め画像検査で仙骨部傍脊髄領域に結節影を認めた。染色体・遺伝子解析よりt(8;21)(q22:q22)/RUNX1-RUNX1T1に加えてKIT D816Y変異を有していた。規定された化学療法終了後に傍脊髄髄外病変に陽子線治療を行ったが、2ヵ月と早期に骨髄再発を認めた。成人ではKIT D816変異陽性SM-AMLは予後不良で造血幹細胞移植の適応とされる。小児SM-AMLの報告は極めて稀で治療方針が確立していないが、小児の予後も成人同様不良である可能性が示唆された。今後、KIT変異検査を加えたSM-AML症例の蓄積をとおして、遺伝子変異を考慮した適切なリスク層別化に基づく治療方針の確立が必要と考える。(著者抄録)

  • Yanagisawa Ryu, Matsuda Kazuyuki, Ohga Shouichi, Kanegane Hirokazu, Morimoto Akira, Okamoto Yasuhiro, Ohara Akira, Fukushima Keitaro, Sotomatsu Manabu, Nomura Keiko, Saito Akiko M., Horibe Keizo, Ishii Eiichi, Nakazawa Yozo .  HLH2004プロトコールで治療を施したEBV関連血球貪食性リンパ組織球症の小児患者における再発の予測因子(Factors predicting the recurrence of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol) .  International Journal of Hematology109 ( 5 ) 612 - 617   2019.5HLH2004プロトコールで治療を施したEBV関連血球貪食性リンパ組織球症の小児患者における再発の予測因子(Factors predicting the recurrence of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol)

     More details

    Publisher:(一社)日本血液学会  

    EBV関連血球貪食性リンパ組織球症の小児患者27例(男性14例、女性13例、平均2.4歳)を対象に、HLH2004プロトコールによる治療後の再発を予測する因子について検討した。EBV関連血球貪食性リンパ組織球症(EBV-HLH)の診断は、HLH2004診断基準に準拠した。原発性HLH、家族性HLH、および悪性腫瘍を有する患者は除外した。末梢血のEBV量を診断時(0週)および治療開始から2週、4週、8週後に測定した。診断時に14例でT細胞受容体クローナリティを認めた。HLH2004プロトコールによる治療後に7例で再発を認めた(再発群)。患者を再発群7例(男性6例、女性1例、平均1.5歳)と寛解群20例(男性8例、女性12例、平均3.2歳)の2群に分類した。診断時のEBV量に有意な群間差はなかったが、治療後2週のEBV量は寛解群の方が有意に低かった(P=0.019)。また診断時の年齢が2歳未満でEBV量が10^3copies/mL以上の患者で再発が有意に多かった(P=0.002)。以上より、EBV-HLH小児患者の年齢と治療早期におけるEBV量は再発の予測因子であることが示唆された。

  • Yanagaisawa R, Matsuda K, Ohga S, Kanegane H, Morimoto A, Okamoto Y, Ohara A, Fukushima K, Sotomatsu M, Nomura K, Saito AM, Horibe K, Ishii E, Nakazawa Y .  Factors predicting the recurrence of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol. .  International journal of hematology109 ( 5 ) 612 - 617   2019.5

  • 1. Nishikawa T, Yamaguchi H, Ikawa K, Nakayama K, Higashi E, Miyahara E, Abematsu T, Nakagawa S, Kodama Y, Tanabe T, Shigemi A, Shinkoda Y, Okamoto Y, Takeda Y, Kawano Y .  Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children. .  Pediatrics International   2019.4Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Yasuhiro Okamoto, Kazuko Kudo, Ken Tabuchi, Daisuke Tomizawa, Takashi Taga, Hiroaki Goto, Hiromasa Yabe, Yozo Nakazawa, Katsuyoshi Koh, Kazuhiro Ikegame, Nao Yoshida, Naoyuki Uchida, Kenichiro Watanabe, Yuuki Koga, Masami Inoue, Koji Kato, Yoshiko Atsuta,Hiroyuki Ishida .  Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia .  Bone Marrow Transplantation   2019.2Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemiaReviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: https://doi.org/10.1038/s41409-019-0461-0

    Other Link: https://rdcu.be/bj7Y3

  • 3. Yanagisawa R, Nakazawa Y, Matsuda K, Yasumi T, Kanegane H, Ohga S, Morimoto A, Hashii Y, Imaizumi M, Okamoto Y, Saito AM, Horibe K, Ishii E .  Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan. .  International Journal of Hematology   2019.2Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Yanagisawa R, Nakazawa Y, Matsuda K, Yasumi T, Kanegane H, Ohga S, Morimoto A, Hashii Y, Imaizumi M, Okamoto Y, Saito AM, Horibe K, Ishii E, HLH, LCH committee, members of the, Japan Children’s Cancer Group .  Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan. .  International journal of hematology109 ( 2 ) 206 - 213   2019.2Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Recent advances in intensive chemo- and immunotherapy have contributed to the outcome of hemophagocytic lymphohistiocytosis (HLH); however, the prognosis of HLH in children differs by HLH subtype. In Japan, secondary HLH, particularly Epstein-Barr virus-associated HLH (EBV-HLH), is the most common HLH subtype. The prognosis of HLH has improved in recent years. We here conducted a prospective study of 73 patients who were treated with HLH-2004 protocol in Japan. EBV-HLH, familial HLH (FHL), and HLH of unknown etiology were seen in 41, 9, and 23 patients, respectively. Patients with resistant or relapsed disease after HLH-2004 treatment and those with FHL received hematopoietic stem cell transplantation (HSCT). The induction rate after initial therapy was 58.9%, and the 3-year overall survival (OS) rate of all patients was 73.9% and differed significantly among those with EBV-HLH, FHL, and HLH of unknown etiology. Of the 17 patients who received HSCT, the 3-year OS rates of those with and without complete resolution before HSCT were 83.3% and 54.5%, respectively. Outcomes in children with HLH who were treated with the same protocol differed among HLH subtypes. Appropriate strategy for each subtype should be established in future studies.

    DOI: 10.1007/s12185-018-02572-z

    Scopus

    PubMed

  • Yanagisawa Ryu, Nakazawa Yozo, Matsuda Kazuyuki, Yasumi Takahiro, Kanegane Hirokazu, Ohga Shouichi, Morimoto Akira, Hashii Yoshiko, Imaizumi Masue, Okamoto Yasuhiro, Saito Akiko M., Horibe Keizo, Ishii Eiichi, HLH/LCH committee members of the Japan Children's Cancer Group .  日本でHLH-2004プロトコールを用いて治療した血球貪食性リンパ組織球症小児の転帰(Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan) .  International Journal of Hematology109 ( 2 ) 206 - 213   2019.2日本でHLH-2004プロトコールを用いて治療した血球貪食性リンパ組織球症小児の転帰(Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan)

     More details

    Publisher:(一社)日本血液学会  

    日本における様々なサブタイプの血球貪食性リンパ組織球症(HLH)小児患者に対するHLH-2004プロトコールの治療成績を評価した。対象患者は73例で、HLH-2004プロトコールに従って初期導入療法を8週間行い、その後、造血幹細胞移植(HSCT)に対して容認できるドナーが得られるまで継続治療を行った。初期療法に対して耐性があるか、治療後に再発した患者に対してもHSCTを用いた。Epstein-Barrウイルス(EBV)-HLHが41例(男児20例、女児21例、年齢0.8〜14.5歳)、家族性HLH(FHL)が9例(男児4例、女児5例、年齢0〜1.4歳)、原因不明のHLHが23例(男児10例、女児13例、年齢0〜14.3歳)であった。全患者の初期療法後の導入率は58.9%で3年全生存率は73.9%で、EBV-HLH、FHL、原因不明のHLHで有意差があった。HSCTを受けた17例では、HSCT前に完全解消した患者の3年全生存率は83.3%で、完全解消のない患者は54.5%であった。同じプロトコールで治療したHLH小児の転帰は、HLHサブタイプによって異なっていた。

  • あべ松 貴成, 岡本 康裕, 安留 悠希, 中村 達郎, 中川 俊輔, 倉内 宏一郎, 児玉 祐一, 西川 拓朗, 田邊 貴幸, 新小田 雄一, 河野 嘉文 .  当科における思春期・若年成人(AYA)世代がんについての検討 .  日本小児科学会雑誌123 ( 2 ) 266 - 266   2019.2当科における思春期・若年成人(AYA)世代がんについての検討

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

  • Okamoto Y. .  Acute lymphoblastic leukemia in down syndrome .  Pediatric Acute Lymphoblastic Leukemia   101 - 108   2019.1

     More details

    Publisher:Pediatric Acute Lymphoblastic Leukemia  

    DOI: 10.1007/978-981-15-0548-5_11

    Scopus

  • 中目 和彦, 山田 和歌, 川野 孝文, 町頭 成郎, 上野 健太郎, 西川 拓朗, 田邊 貴幸, 向井 基, 義岡 孝子, 岡本 康裕, 加治 建, 河野 嘉文, 家入 里志 .  腫瘍破裂により心タンポナーデをきたした縦隔成熟奇形腫の1小児例 .  日本小児血液・がん学会雑誌55 ( 5 ) 427 - 431   2019.1腫瘍破裂により心タンポナーデをきたした縦隔成熟奇形腫の1小児例

     More details

    Publisher:(一社)日本小児血液・がん学会  

    今回、腫瘍破裂により心タンポナーデに至った縦隔成熟奇形腫の症例を経験したので報告する。症例は8歳、女児。肩痛、血痰を主訴に受診し、CT検査にて左前縦隔奇形腫が疑われた。AFPとHCGは正常であった。初診時より12日後に手術が予定されたが、術前に全身倦怠感、発熱を認め、CRP9.68mg/dLと高値を認めた。造影CT検査にて腫瘍増大と心嚢液貯留を認め、その後心嚢液貯留は増悪し、呼吸困難が出現した。緊急の心嚢穿刺・ドレナージが施行され、血性の心嚢液を認めた。心嚢液貯留は持続し、貧血も進行したため緊急の開胸腫瘍摘出術を施行した。病理組織診断は成熟奇形腫で、術後に心嚢液貯留は改善した。良性縦隔成熟奇形腫であっても腫瘍増大に伴う周囲臓器への破裂により重篤な合併症をきたす可能性があり、正確な術前評価と注意深い病態変化の観察が必要である。(著者抄録)

  • 楠田 政輝, 岡本 康裕, 中川 俊輔, 児玉 祐一, 西川 拓朗, 松阪 康弘, 國廣 誉世, 岡田 恵子, 義岡 孝子, 河野 嘉文 .  部分切除・放射線療法後、エトポシドで寛解となった脊髄退形成性星細胞腫の乳児例 .  日本小児血液・がん学会雑誌55 ( 5 ) 417 - 420   2019.1部分切除・放射線療法後、エトポシドで寛解となった脊髄退形成性星細胞腫の乳児例

     More details

    Publisher:(一社)日本小児血液・がん学会  

    症例は6ヵ月男児。生後4ヵ月時から両下肢の対麻痺があり、脊髄MRI検査でTh7-L1に髄内腫瘍を認めた。部分摘出術を施行し、病理検査所見より退形成性星細胞腫(Grade III)と診断した。切除後の造影MRI検査では下位脊髄〜脊髄円錐に48mm×10mm大の残存病変を認めた。放射線治療(1.5Gy/回、計36Gy/24回)を施行し、病変は43mm×5mmに縮小し、両下肢の対麻痺は改善した。エトポシド内服(25mg/日×11日)による化学療法14コース終了後(発症から1年6ヵ月)には病変は消失した。現在発症から1年7ヵ月まで再発なく経過している。退形成性星細胞腫においては肉眼的腫瘍摘出術および放射線療法が治療の基本で、化学療法の意義は確立されていない。本症例においては部分切除後・放射線科治療後に大きな残存病変を認めたが、エトポシド内服とともに腫瘍が消失し、エトポシドが奏功した可能性が考えられる。(著者抄録)

  • 中目 和彦, 山田 和歌, 川野 孝文, 町頭 成郎, 上野 健太郎, 西川 拓朗, 田邊 貴幸, 向井 基, 義岡 孝子, 岡本 康裕, 加治 建, 河野 嘉文, 家入 里志 .  腫瘍破裂により心タンポナーデをきたした縦隔成熟奇形腫の1小児例 .  日本小児血液・がん学会雑誌55 ( 5 ) 427 - 431   2019.1

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    今回、腫瘍破裂により心タンポナーデに至った縦隔成熟奇形腫の症例を経験したので報告する。症例は8歳、女児。肩痛、血痰を主訴に受診し、CT検査にて左前縦隔奇形腫が疑われた。AFPとHCGは正常であった。初診時より12日後に手術が予定されたが、術前に全身倦怠感、発熱を認め、CRP9.68mg/dLと高値を認めた。造影CT検査にて腫瘍増大と心嚢液貯留を認め、その後心嚢液貯留は増悪し、呼吸困難が出現した。緊急の心嚢穿刺・ドレナージが施行され、血性の心嚢液を認めた。心嚢液貯留は持続し、貧血も進行したため緊急の開胸腫瘍摘出術を施行した。病理組織診断は成熟奇形腫で、術後に心嚢液貯留は改善した。良性縦隔成熟奇形腫であっても腫瘍増大に伴う周囲臓器への破裂により重篤な合併症をきたす可能性があり、正確な術前評価と注意深い病態変化の観察が必要である。(著者抄録)

  • HARAO Takuro, OKAMOTO Yasuhiro, KAWANO Yoshifumi, MORITAKE Hiroshi, YAMADA Ai, KINOSHITA Mariko, SAWA Daisuke, SAITO Yusuke, KAMIMURA Sachiyo, MIYACHI Hayato, OGINO Takashi, KODAMA Yuichi .  Acute myeloid leukemia evolving from <i>KIT</i> D816-mutated systemic mastocytosis relapsing two months after completion of chemotherapy .  Rinsho Ketsueki60 ( 5 ) 378 - 381   2019

     More details

    Publisher:The Japanese Society of Hematology  

    <p>Here, we report the case of a 9-year-old girl with acute myeloid leukemia (AML) developed from systemic mastocytosis (SM). She experienced bladder and rectal disturbance due to an extramedullary nodule in the paraspinal region of the sacrum. Cytogenetic and genetic analyses of leukemic cells revealed the <i>KIT</i> D816Y mutation besides t (8;21) (q22:q22) /<i>RUNX1</i>-<i>RUNX1T1</i>. Despite receiving proton beam therapy after conventional chemotherapy, the patient relapsed after 2 months. As SM-AML with the <i>KIT</i> D816 mutation in adults exhibits a poor prognosis, hematopoietic stem cell transplantation is recommended. Owing to a few reports of SM-AML in children, the standard therapy for pediatric cases has not been established to date. Based on our experience and the related literature, the prognosis of childhood SM-AML could be as poor as in adults. Hence, further investigation, including mutational analyses of the <i>KIT</i> gene, is warranted to establish a risk-oriented strategy for managing childhood SM-AML.</p>

    DOI: 10.11406/rinketsu.60.378

    PubMed

  • Imamura M. .  Celecoxib as a potential treatment for intractable lymphatic malformation .  Pediatrics144 ( 3 )   2019

     More details

    Publisher:Pediatrics  

    DOI: 10.1542/peds.2019-0319

    Scopus

    PubMed

  • Seki Y. .  Slowly progressive acute lymphoblastic leukemia after stem cell transplantation .  Pediatrics International61 ( 8 ) 831 - 832   2019

     More details

    Publisher:Pediatrics International  

    DOI: 10.1111/ped.13932

    Scopus

    PubMed

  • 井上 一利, 河野 嘉文, 西川 拓朗, 平木 翼, 佐々木 裕美, 義岡 孝子, 中川 俊輔, 児玉 祐一, 岡本 康裕, 谷本 昭英 .  診断に難渋した前腕原発spindle cell sarcomaの1例 .  日本小児血液・がん学会雑誌56 ( 2 ) 212 - 215   2019

     More details

    Publisher:日本小児血液・がん学会  

    <p>1歳9か月の男児.左前腕部の腫脹に気付き紹介医を受診,MRI検査で6 cm弱の充実性腫瘤を認め当科紹介となった.転移巣なく,生検術を行った.当初,生検材料の病理検索ではinfantile fibrosarcomaを考えたが,中央病理診断ではmyofibromaが疑われた.臨床的な判断に基づいて,vincristine,actinomycine,ifosfamideによる化学療法を開始したが,腫瘍径は変化なかった.中央病理診断の結果と治療反応から,化学療法は開始2か月で中止した.中止3か月後より腫瘤が増大し,中止4か月後に腫瘍辺縁切除術を行った.この際の病理診断はspindle cell sarcoma, unclassifiedであった.局所照射,vincristine,ifosfamide,doxorubicinによる化学療法を3クール行い治療終了した.病理診断が臨床経過に合わない場合は,再度検体を採取し,病理検査を行うことを考慮する.</p>

    DOI: 10.11412/jspho.56.212

  • Sugita Koshiro, Ieiri Satoshi, Kawano Takafumi, Moriguchi Tomoe, Onishi Shun, Ikee Takamasa, Kodama Yuichi, Nishikawa Takuro, Okamoto Yasuhiro, Kaji Tatsuru .  Two Cases of Pediatric Colorectal Cancer .  Journal of the Japanese Society of Pediatric Surgeons55 ( 5 ) 968 - 976   2019

     More details

    Publisher:The Japanese Society of Pediatric Surgeons  

    <p>We experienced treating two patients with colonic cancer diagnosed at school age and adolescence. Neither patient had a family history of cancer. [Case 1] A 14-year-old boy presented with the chief complaints of appetite loss and weight loss. He was referred to our hospital because of anemia and abdominal tumor noted on computed tomography (CT) images. Enhanced CT showed a circumferential elevated lesion in which the lumen was completely occluded along with multiple polyps. Left hemicolectomy and D2 + paraaortic lymph node dissection were performed. The resected tumor was diagnosed as adenocarcinoma, and the pathological stage was IV. Subsequently, chemotherapy was performed. However, he died one year after the operation owing to recurrence and metastasis. [Case 2] A 10-year-old boy presented with the chief complaints of bloody stool and abdominal pain. He was referred to our hospital owing to a diagnosis of intussusception based on contrast-enhanced CT findings. Emergency laparoscopic exploration was performed to assess the tumor. The tumor was suspected to be malignant lymphoma, and local excision was performed. The pathological diagnosis was mucinous carcinoma. Laparoscopic left hemicolectomy and lymph node dissection of D3 were performed similarly to the treatment of adult colon cancer. The final pathological diagnosis was stage IIIb, and chemotherapy was performed. The patient experienced no recurrence for two years after operation. [Conclusion] Colorectal cancer in children is extremely rare, but it is necessary to identify it correctly when gastrointestinal symptoms are prolonged.</p>

    DOI: 10.11164/jjsps.55.5_968

  • あべ松 貴成, 岡本 康裕, 中川 俊輔, 倉内 宏一郎, 児玉 祐一, 西川 拓朗, 田邊 貴幸, 新小田 雄一, 畠中 美帆, 義岡 孝子, 河野 嘉文 .  早期の想定が功を奏した急性骨髄性白血病の骨髄移植後に発症した播種性皮膚ムコール感染症例(Early suspicion of disseminated cutaneous mucormycosis leading to successful treatment after bone marrow transplantation in a patient with acute myeloid leukemia) .  日本小児血液・がん学会雑誌55 ( 3 ) 298 - 303   2018.10早期の想定が功を奏した急性骨髄性白血病の骨髄移植後に発症した播種性皮膚ムコール感染症例(Early suspicion of disseminated cutaneous mucormycosis leading to successful treatment after bone marrow transplantation in a patient with acute myeloid leukemia)

     More details

    Publisher:(一社)日本小児血液・がん学会  

    播種性のムコール感染症は致死的な疾患である。早期診断が必要不可欠だが、生物学的指標物質はなく診断は困難である。我々は治療が奏効した急性骨髄性白血病に合併した播種性皮膚ムコール感染症例を経験した。治療による骨髄抑制や原疾患の悪化に伴う重症の好中球減少や単球減少、血液悪性疾患、骨髄移植症例であったこと、輸血による鉄過剰状態であったこと、ポリコナゾールの先行投与があったことなど多数のリスク因子に基づき、ムコール感染を想定して確定診断前にアムホテリシンBの投与を行った。皮膚病変は外科的切除なしに改善した。血液悪性腫瘍の診療の現場において、ムコール感染症のリスク因子の理解に基づいた迅速な治療が必要不可欠である。(著者抄録)

  • Nakagawa S, Okamoto Y, Kodama Y, Nishikawa T, Tanabe T, Kawano Y .  Importance of Acute Lymphoblastic Leukemia-type Therapy for Bilineal Acute Leukemia. .  Journal of pediatric hematology/oncology41 ( 6 ) 504 - 506   2018.9

  • Seki Y, Okamoto Y, Kodama Y, Nishikawa T, Tanabe T, Nakagawa S, Mizota M, Kawano Y .  Risk Factors and the Prevention of Weight Gain During Induction Chemotherapy in Children With Acute Lymphoblastic Leukemia. .  Journal of pediatric hematology/oncology40 ( 6 ) e334 - e337   2018.8

  • Seki Y, Okamoto Y .  Risk Factors and the Prevention of Weight Gain During Induction Chemotherapy in Children With Acute Lymphoblastic. .  Journal of pediatric hematology/oncology41 ( 1 ) 79 - 80   2018.8

  • Koh K, Kato M, Saito AM, Kada A, Kawasaki H, Okamoto Y, Imamura T, Horibe K, Manabe A .  Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan. .  Japanese journal of clinical oncology48 ( 7 ) 684 - 691   2018.7

  • Saito A, Nishikawa T, Oyoshi T, Nakagawa S, Kodama Y, Yamada A, Kinoshita M, Okamoto Y, Arita K, Moritake H, Kawano Y .  Giant radiation-induced cavernous haemangioma before reduced-intensity bone marrow transplantation for acute lymphoblastic leukaemia. .  Bone marrow transplantation54 ( 2 ) 312 - 315   2018.7

  • Itesako T, Eura R, Okamoto Y, Tatarano S, Yoshino H, Nishimura H, Yamada Y, Enokida H, Nakagawa M .  Oral Propranolol in a Child With Infantile Hemangioma of the Urethra. .  Urology122   165 - 168   2018.6

  • 中川 俊輔, 岡本 康裕, 児玉 祐一, 西川 拓朗, 田邊 貴幸, 河野 嘉文 .  高リスク髄芽腫の再発後にtemozolomide単剤で長期生存している小児例 .  日本小児血液・がん学会雑誌55 ( 1 ) 33 - 36   2018.6高リスク髄芽腫の再発後にtemozolomide単剤で長期生存している小児例

     More details

    Publisher:(一社)日本小児血液・がん学会  

    再発髄芽腫に対するtemozolomide(TMZ)の報告は本邦ではまだない。症例は6歳の男児で、小脳原発の高リスク髄芽腫(desmoplastic type、術後の脊髄MRIで播種病変あり)と診断された。脳腫瘍摘出術と放射線照射後に寛解を確認した。術後化学療法(ifosfamide、cisplatin、etoposide)と自家末梢血幹細胞移植を併用した大量化学療法(busulfan、melphalan)を行った。術後24ヵ月後のMRIで右側脳室、右側頭葉、左小脳半球に腫瘤性病変を認め再発と診断した。欧米からの有効性があるという既報を参考に、TMS(150mg/m2/日×5、4週間毎)の内服で治療を開始した。腫瘍は残存しているが縮小傾向で、再発後28ヵ月が経過し、TMZを30サイクル行った。副作用もほとんど認めず、良好なQOLを維持できている。TMZは髄芽腫の再発に対する化学療法として有用な可能性がある。(著者抄録)

  • Nakagawa Shunsuke, Okamoto Yasuhiro, Kodama Yuichi, Nishikawa Takuro, Tanabe Takayuki, Kawano Yoshifumi .  Thiamylal Plus Pentazocine Shows Similar Efficacy as Ketamine Plus Midazolam for Painful Procedures in Children With Leukemia .  JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY40 ( 4 ) E263 - E265   2018.5Thiamylal Plus Pentazocine Shows Similar Efficacy as Ketamine Plus Midazolam for Painful Procedures in Children With Leukemia

  • 野口 磨依子, 稲垣 二郎, 岡本 康裕, 古賀 友紀, 大園 秀一, 新小田 雄一, 中山 秀樹, 盛武 浩, 堀田 紀子, 糸長 伸能, 野村 優子, 下之段 秀美, 市村 卓也, 日高 靖文, 河野 嘉文 .  小児急性リンパ性白血病のvery late relapse例の予後 九州・山口小児がん治療研究グループ(KYCCSG)ALL 96/02研究 .  日本小児血液・がん学会雑誌54 ( 5 ) 393 - 397   2018.4小児急性リンパ性白血病のvery late relapse例の予後 九州・山口小児がん治療研究グループ(KYCCSG)ALL 96/02研究

     More details

    Publisher:(一社)日本小児血液・がん学会  

    小児急性リンパ性白血病(acute lymphoblastic leukemia:ALL)の初回治療後再発率は約20%とされ、再発時期は治療中から治療終了後早期に多いため、長期間寛解を維持した後の再発(very late relapse:VLR)症例の報告は少ない。今回、九州・山口小児がん治療研究グループ(KYCCSG)ALL-96/02プロトコールで治療を行った初発小児ALL患者のうち、治療終了後24ヵ月以降の再発例をVLRとし、その臨床的特徴と予後を検討した。KYCCSG ALL-96/02に登録・治療された357症例のうち全再発例は70例(19.6%)であった。VLRは8例(2.2%)であり、治療終了から再発までの期間の中央値は37.5ヵ月(範囲26-42ヵ月)であった。初診時リスク分類は標準リスク群が6例、高リスク群が2例で、再発部位は骨髄単独が6例、精巣単独が1例、骨髄+中枢神経が1例であった。8例すべてにおいて再寛解導入療法後第2寛解に至った。同種移植を受けた3例中1例は、移植後11ヵ月で再発し死亡した。その他の7例は再発後の観察期間57ヵ月(範囲32-92ヵ月)で寛解生存しており、VLR症例の予後は良好と考えられた。(著者抄録)

  • Yatsushiro Y, Nishikawa T, Saito A, Nakazawa Y, Imadome KI, Nakagawa S, Kodama Y, Okamoto Y, Kanegane H, Kawano Y .  Epstein-Barr Virus (EBV)-induced B-cell Lymphoproliferative Disorder Mimicking the Recurrence of EBV-associated Hemophagocytic Lymphohistiocytosis. .  Journal of pediatric hematology/oncology41 ( 1 ) E44 - E46   2018.1Reviewed

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Ovid Technologies (Wolters Kluwer Health)  

    DOI: 10.1097/MPH.0000000000001075

    Scopus

    PubMed

  • Nakame Kazuhiko, Okamoto Yasuhiro, Kaji Tatsuru, Kawano Yoshifumi, Ieiri Satoshi, Yamada Waka, Kawano Takafumi, Machigashira Seiro, Ueno Kentarou, Nishikawa Takurou, Tanabe Takayuki, Mukai Motoi, Yoshioka Takako .  Mediastinal mature teratoma causing cardiac tamponade—A pediatric case report .  The Japanese Journal of Pediatric Hematology / Oncology55 ( 5 ) 427 - 431   2018

     More details

    Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    <p>We report the case of an 8-year-old girl with a mediastinal mature teratoma causing cardiac tamponade, who showed shoulder pain and hemosputum. She was transferred to our hospital and diagnosed as having mediastinal mature teratoma by computed tomography (CT). Her tumor marker levels were within the normal ranges. Tumor extirpation was planned, but general fatigue and fever elevation were recognized on admission. Tumor enlargement and pericardial effusion were detected by enhanced CT. Pericardial drainage was performed for cardiac tamponade induced by progressive pericardial effusion. Bloody fluid was recognized and the patient showed severe anemia requiring blood transfusion. Emergent tumor extirpation was performed through left thoracotomy. The histopathological findings showed a benign mature teratoma. The postoperative course was uneventful and her pericardial effusion gradually decreased after surgery. Mediastinal mature teratoma sometimes causes serious complications affecting surrounding organs due to tumor rupture. Careful follow-up is required for patients with mediastinal mature teratoma.</p>

    DOI: 10.11412/jspho.55.427

  • Nakagawa Shunsuke, Okamoto Yasuhiro, Kodama Yuichi, Nishikawa Takuro, Tanabe Takayuki, Kawano Yoshifumi .  Long-term survival of a pediatric patient with relapsed high-risk medulloblastoma treated with temozolomide .  The Japanese Journal of Pediatric Hematology / Oncology55 ( 1 ) 33 - 36   2018

     More details

    Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    <p>Temozolomide (TMZ) has recently been used for relapsed medulloblastoma; however, its use is limited in Japan. A 6-year-old boy with high-risk medulloblastoma in the cerebellum was treated by surgery, radiotherapy, and chemotherapy consisting of ifosfamide, cisplatin, and etoposide, followed by high-dose chemotherapy consisting of busulfan and melphalan and rescued by autologous stem cell transplantation. Twenty-four months after surgery, the medulloblastoma relapsed in the right lateral ventricle, temporal lobe, and left cerebellar hemisphere. Oral temozolomide [150 mg/m<sup>2</sup> once daily for 5 days, repeated every 28 days (one cycle)] was started as a palliative therapy. To date, temozolomide has been repeated for 30 cycles for 28 months and the relapsed lesions have become smaller. The adverse effects of temozolomide on the patient were mild, and he was able to live with a good quality of life. Temozolomide is a good agent for medulloblastoma relapse.</p>

    DOI: 10.11412/jspho.55.33

    J-GLOBAL

  • Abematsu Takanari, Yoshioka Takako, Kawano Yoshifumi, Okamoto Yasuhiro, Nakagawa Shunsuke, Kurauchi Koichiro, Kodama Yuichi, Nishikawa Takuro, Tanabe Takayuki, Shinkoda Yuichi, Hatanaka Miho .  Early suspicion of disseminated cutaneous mucormycosis leading to successful treatment after bone marrow transplantation in a patient with acute myeloid leukemia .  The Japanese Journal of Pediatric Hematology / Oncology55 ( 3 ) 298 - 303   2018

     More details

    Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    <p>Mucormycosis can be life-threatening, especially when the infection is disseminated. Early diagnosis is essential, although a lack of specific biomarkers renders this difficult. We present the case of a patient with acute myeloid leukemia with disseminated cutaneous mucormycosis treated successfully. We initiated liposomal amphotericin B treatment before a definitive diagnosis was made, basing the decision on the presence of multiple risk factors for mucormycosis, such as severe neutropenia and monocytopenia due to bone marrow suppression and exacerbation of the primary disease, malignant hematological disease, bone marrow transplantation, excess iron due to blood transfusion, and precedent initiation of voriconazole. The skin lesions improved without surgical resection. This case illustrates that understanding the risk factors for mucormycosis and prompt administration of appropriate therapy are essential for its treatment in patients with hematological malignancies.</p>

    DOI: 10.11412/jspho.55.298

  • Kusuda Masaki, Kawano Yoshifumi, Okamoto Yasuhiro, Nakagawa Shunsuke, Kodama Yuichi, Nishikawa Takuro, Matsusaka Yasuhiro, Kunihiro Noritsugu, Okada Keiko, Yoshioka Takako .  An infant with spinal anaplastic astrocytoma achieving complete remission after partial resection followed by etoposide treatment .  The Japanese Journal of Pediatric Hematology / Oncology55 ( 5 ) 417 - 420   2018

     More details

    Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    <p>A 6-month-old infant developed paraplegia at 4 months of age. Spinal magnetic resonance imaging (MRI) revealed an intramedullary tumor in Th7-L1. Partial excisional surgery was performed, and a diagnosis of anaplastic astrocytoma (grade III) was made. MRI revealed a large residual lesion (48 mm×10 mm) after resection. Radiotherapy with a total dose of 36 Gy in 24 fractions was performed, but the lesion remained with a size of 43 mm×5 mm, although paraplegia of both lower limbs improved. After 14 courses of oral administration of etoposide (25 mg/day for 11 days), no residual lesion was observed. No recurrence has been detected for 19 months from the disease onset. In anaplastic astrocytoma, complete resection and radiotherapy are the main treatments, whereas the significance of chemotherapy has not been established. Our patient showed that remission could be achieved by administering etoposide for anaplastic astrocytoma even after partial resection.</p>

    DOI: 10.11412/jspho.55.417

  • Shunsuke Nakagawa, Yasuhiro Okamoto, Yuichi Kodama, Takuro Nishikawa, Takayuki Tanabe, Yoshifumi Kawano .  Thiamylal Plus Pentazocine Shows Similar Efficacy as Ketamine Plus Midazolam for Painful Procedures in Children with Leukemia .  Journal of Pediatric Hematology/Oncology40 ( 4 ) e263 - e265   2018Reviewed

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Lippincott Williams and Wilkins  

    This retrospective study compared the use of thiamylal plus pentazocine (TP) to ketamine plus midazolam (KM) in children with leukemia who were undergoing bone marrow aspiration and/or intrathecal chemotherapy. A total of 268 procedures in 35 children with leukemia were retrospectively analyzed for efficacy and adverse events. All procedures were successfully completed without severe adverse events. TP induced significantly faster sedation. The incidents of desaturation were significantly greater in the TP group, but were transient and recovered by oxygen supplementation alone. Therefore, TP can be a useful combination with a similar efficacy as KM for painful procedures in children.

    DOI: 10.1097/MPH.0000000000001053

    Scopus

    PubMed

  • 岡本 康裕 .  ダウン症候群に合併した急性リンパ性白血病 .  日本小児血液・がん学会雑誌55 ( 3 ) 217 - 222   2018

     More details

    Publisher:日本小児血液・がん学会  

    <p>ダウン症候群(DS)において急性リンパ性白血病(ALL)の発症する頻度は,非DS-ALLの20倍とされる.21番染色体上にあるHMGN1の働きでリンパ系の増殖が起こり,さらにP2RY8-CRLF2融合などによるCRLF2の過剰発現により,JAK-STATの活性化が起こり,ALL細胞が増殖するという機序が考えられる.このCRLF2の融合はDS-ALLの50–60%に認められる.現在,CRLF2の下流のPI3KとmTORの阻害薬や,TSLPR/CRLF2抗体などが開発中で,JAK2阻害薬は第二相試験が米国で開始された.世界の研究グループからの658例を対象とした後方視的研究では,DS-ALLの8年無病生存率は64%で,非DS-ALLの81%より有意に低い.DS-ALLでは,予後良好である高二倍体やETV6-RUNX1異常などが少ないこと,予後不良のCRLF2の異常が多いこと,また粘膜障害,感染合併症などによる副作用死亡が多いために,ALLの治療成績の向上の歴史から取り残された.しかし,最近のDana-Farber癌研究所の報告では,38例と少数であるが,5年無病生存率が91%で,非DS-ALLと差がなかった.微小残存病変などによるリスクに応じた適切な治療や,適切な副作用対策を行えば,DS-ALLの治療成績が改善する可能性がある.このためDS-ALLを独立した疾患として特化した臨床研究が望まれる.DS-ALLの希少性を克服するために,シンガポール,マレーシア,台湾,香港と日本が参加する国際共同研究が2018年に始まった.微小残存病変をフローサイトメトリー法によって評価し,予後良好群では治療を軽減する.本試験によりDS-ALLに対する標準治療が確立され,さらに特異的な治療が開発されることが期待される.</p>

    DOI: 10.11412/jspho.55.217

  • Ishimaru Sae, Okamoto Yasuhiro, Imai Chihaya, Sakaguchi Hirotoshi, Taki Tomohiko, Hasegawa Daisuke, Cho Yuko, Kakuda Harumi, Sano Hideki, Manabe Atushi, Imamura Toshihiko, Kato Motohiro, Arakawa Yuki, Shimonodan Hidemi, Sato Atsushi, Suenobu So-ichi, Inukai Takeshi, Watanabe Arata, Kawano Yoshifumi, Kikuta Atsushi, Horibe Keizo, Ohara Akira, Koh Katsuyoshi .  Nationwide Survey of Pediatric Hypodiploid Acute Lymphoblastic Leukemia in Japan .  BLOOD130   2017.12Nationwide Survey of Pediatric Hypodiploid Acute Lymphoblastic Leukemia in Japan

     More details

  • 5. Kodama Y, Okamoto Y, Kubota T, Hiroyama Y, Fukami H, Matsushita K, Kawano Y .  Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy. .  Brain Dev   2017.11Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Yuichi Kodama, Yasuhiro Okamoto, Tomohiro Kubota, Yoshifumi Hiroyama, Hiroshi Fukami, Kensuke Matsushita, Yoshifumi Kawano .  Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy .  BRAIN & DEVELOPMENT39 ( 10 ) 846 - 850   2017.11

     More details

    Publisher:ELSEVIER SCIENCE BV  

    Background: Osteoporosis can lead to spontaneous fractures in adults with cerebral palsy (CP). Undercarboxylated osteocalcin (ucOC) is a useful marker for vitamin K insufficiency in osteoporosis. The primary objective of this study was to determine the effect of vitamin K2 on bone mineral density (BMD) in adults with CP and vitamin K insufficiency.
    Methods: Sixteen adults, median age of 56 years, with CP and osteoporosis in whom the serum ucOC concentration exceeded 4.5 ng/mL were included. All patients received 45 mg of vitamin K2 per day. BMD was measured and presented as a percentage of the young adult mean (%YAM). Serum levels of ucOC and BMD were measured at baseline and after 6 and 12 months.
    Results: Serum levels of ucOC decreased from 7.8 ng/mL (range, 4.9-32) at baseline to 3.9 ng/mL (range, 1.9-6.8) after 6 months (P = 0.001). BMD increased from 59%YAM (range, 45-67) at baseline to 68%YAM (range, 5-079) after 12 months (P = 0.003).
    Conclusions: Vitamin K2 had a positive effect on BMD in osteoporotic adults with CP and high serum concentrations of ucOC, and might be useful as a first line treatment for osteoporotic adults with CP and vitamin K insufficiency. (C) 2017 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

    DOI: 10.1016/j.braindev.2017.05.012

    Web of Science

    Scopus

    PubMed

  • Yasuhiro Okamoto, Shunsuke Nakagawa, Takanari Abematsu, Yuichi Kodama, Takuro Nishikawa, Takayuki Tanabe, Yuichi Shinkoda, Yoshifumi Kawano .  Outcomes After First Relapse in Children with Solid Tumors in an Era Without Novel Treatments .  PEDIATRIC BLOOD & CANCER64   S37 - S37   2017.11Outcomes After First Relapse in Children with Solid Tumors in an Era Without Novel Treatments

     More details

    Publisher:WILEY  

    Web of Science

  • Kodama Yuichi, Okamoto Yasuhiro, Kubota Tomohiro, Hiroyama Yoshifumi, Fukami Hiroshi, Matsushita Kensuke, Kawano Yoshifumi .  成人脳性麻痺例の骨粗鬆症に対するビタミンK2の有効性(Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy) .  Brain & Development39 ( 10 ) 846 - 850   2017.11成人脳性麻痺例の骨粗鬆症に対するビタミンK2の有効性(Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy)

     More details

    Publisher:エルゼビア・ジャパン(株)  

    ビタミンKが不足している成人脳性麻痺例の骨粗鬆症に対してビタミンK2補給が有効か調べた。骨粗鬆症と診断した脳性麻痺患者で、血清低カルボキシル化オステオカルシン(ucOC)濃度が4.5ng/mLを超える16例(男性9例、女性7例、年齢42〜69歳)を対象とした。ビタミンK2 45mg/日を服用し、ベースラインと6、12ヵ月後に骨密度と血清ucOC値を測定した。骨密度は若年成人平均値の比率(%YAM)として示した。血清ucOC値はベースラインの7.8ng/mLから6ヵ月後には3.9ng/mLに減少したが、12ヵ月後は4.4ng/mLで6ヵ月後と有意差はなかった。骨密度はベースラインの59%YAMから6ヵ月後には64%YAM、12ヵ月後には68%YAMへと有意に増加した。ビタミンK2は、ビタミンK不足の脳性麻痺患者の骨粗鬆症に対するファーストライン治療薬として使用できると考えられた。

  • Koichiro Kurauchi, Takuro Nishikawa, Emiko Miyahara, Yasuhiro Okamoto, Yoshifumi Kawano .  Role of metabolites of cyclophosphamide in cardiotoxicity .  BMC Research Notes10 ( 1 ) 406   2017.8

     More details

    Publisher:BioMed Central Ltd.  

    Background: The dose-limiting toxic effect of cyclophosphamide (CY) is cardiotoxicity. The pathogenesis of myocardial damage is poorly understood, and there is no established means of prevention. In previous studies, we suggested that for CY-induced cardiotoxicity, whereas acrolein is the key toxic metabolite, carboxyethylphosphoramide mustard (CEPM) is protective. We sought to verify that acrolein is the main cause of cardiotoxicity and to investigate whether aldehyde dehydrogenase (ALDH), which is associated with greater CEPM production, is involved in the protective effect for cardiotoxicity. We also evaluated the protective effect of N-acetylcysteine (NAC), an amino acid with antioxidant activity and a known acrolein scavenger. Methods: H9c2 cells were exposed to CY metabolites HCY (4-hydroxy-cyclophosphamide), acrolein or CEPM. The degree of cytotoxicity was evaluated by MTT assay, lactate dehydrogenase (LDH) release, and the production of reactive oxygen species (ROS). We also investigated how the myocardial cellular protective effects of CY metabolites were modified by NAC. To quantify acrolein levels, we measured the culture supernatants using high performance liquid chromatography. We measured ALDH activity after exposure to HCY or acrolein and the same with pre-treatment with NAC. Results: Exposure of H9c2 cells to CEPM did not cause cytotoxicity. Increased ROS levels and myocardial cytotoxicity, however, were induced by HCY and acrolein. In cell cultures, HCY was metabolized to acrolein. Less ALDH activity was observed after exposure to HCY or acrolein. Treatment with NAC reduced acrolein concentrations. Conclusions: Increased ROS generation and decreased ALDH activity confirmed that CY metabolites HCY and acrolein are strongly implicated in cardiotoxicity. By inhibiting ROS generation, increasing ALDH activity and decreasing the presence of acrolein, NAC has the potential to prevent CY-induced cardiotoxicity.

    DOI: 10.1186/s13104-017-2726-2

    Scopus

    PubMed

  • Naohiro Ikeda, Shinsuke Maruyama, Kanna Nakano, Ryo Imakiire, Yumiko Ninomiya, Shunji Seki, Kosuke Yanagimoto, Yasuyuki Kakihana, Keiichi Hara, Go Tajima, Yasuhiro Okamoto, Yoshifumi Kawano .  A surviving 24-month-old patient with neonatal-onset carnitine palmitoyltransferase II deficiency .  Molecular Genetics and Metabolism Reports11   69 - 71   2017.6

     More details

    Publisher:Elsevier Inc.  

    The early-onset form of carnitine palmitoyltransferase (CPT) II deficiency has severe outcomes
    patients typically die during the newborn period. We report a case of neonatal-onset CPT II deficiency with prolonged survival, exceeding 24 months. The patient was successfully treated by continuous hemodialysis (CHD), which enabled her to overcome repeated crises. We suggest that early intensive treatment, including CHD, is a key for prolonged survival in patients with neonatal-onset CPT II deficiency.

    DOI: 10.1016/j.ymgmr.2017.04.010

    Web of Science

    Scopus

    PubMed

  • 野村 優子, 西川 拓朗, 岡本 康裕, 河野 嘉文, 廣瀬 伸一 .  化学療法中の骨減少症に対してビスフォスフォネート製剤を開始した小児急性リンパ性白血病の3症例 .  日本小児血液・がん学会雑誌53 ( 5 ) 474 - 476   2017.3化学療法中の骨減少症に対してビスフォスフォネート製剤を開始した小児急性リンパ性白血病の3症例

     More details

    Publisher:(一社)日本小児血液・がん学会  

    小児の急性リンパ性白血病(ALL)では骨減少症を合併しうる。小児におけるビスフォスフォネート(BP)の使用は増えているが、化学療法中のBPの安全性や有効性は確立されていない。今回、九州山口小児がん研究グループALL-96およびALL-02に登録した小児B前駆型ALLのうち、化学療法中にBPを使用した3症例を報告する。3例のALL発症時年齢は3(9歳時に再発)、11、16歳で、いずれも維持療法中の11(第2寛解期)、13、19歳時に骨減少症と診断された。週1回のBP内服(アレンドロン酸35mg、またはリセドロン酸17.5mg)を30〜72ヵ月以上行ったが副作用は認めなかった。2例では、Zスコアが-2.4から-0.2、-3.7から-1.4へと改善した。全例で予定の化学療法を終了し、3年〜5年7ヵ月間寛解を維持している。化学療法中でもBPは安全に使用することができた。(著者抄録)

  • 6. Sripornsawan P, Okamoto Y*, Nishikawa T, Kodama Y, Yamaki Y, Kurauchi K, Tanabe T, Nakagawa S, Shinkoda Y, Imuta N, Kawano Y. .  Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma .  Pediatr Blood Cancer   2017.2Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphomaReviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Pornpun Sripornsawan, Yasuhiro Okamoto, Takuro Nishikawa, Yuichi Kodama, Yuni Yamaki, Koichiro Kurauchi, Takayuki Tanabe, Shunsuke Nakagawa, Yuichi Shinkoda, Naoko Imuta, Yoshifumi Kawano .  Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma .  PEDIATRIC BLOOD & CANCER64 ( 2 ) 250 - 253   2017.2

     More details

    Publisher:WILEY-BLACKWELL  

    Background: Nelarabine has been used for the treatment of T-cell malignancies including T-acute lymphoblastic leukemia (T-ALL)/T-lymphoblastic lymphoma. However, the mechanisms that underlie the susceptibility or resistance to nelarabine have not been fully elucidated. The aim of this study was to determine the significance of nelarabine transport and metabolism in the context of nelarabine cytotoxicity.
    Procedure: The expression profiles of six genes in the nelarabine pathway were analyzed in blast cells from six patients with T-ALL as well as in three T-ALL cell lines. In vitro cytotoxicity (LC50 of 9-beta-D-arabinofuranosylguanine [ara-G]) was evaluated.
    Results: The mRNA expression of ENT1, DCK, CDA, NT5C2, RRM1, and RRM2 in patients showed inter-individual variability and was not correlated with the LC50 of ara-G. However, the ratio of (ENT1 x DCK)/(CDA x RRM1) expression was significantly correlated with LC50 (r = -0.831, P = 0.0405).
    Conclusions: Chemosensitivity to nelarabine is influenced by the balance of the expression of these four genes, and the ratio of their expression predicts the response of T-cell malignancies to nelarabine.

    DOI: 10.1002/pbc.26214

    Web of Science

    Scopus

    PubMed

  • Kosuke Yanagimoto, Yasuhiro Okamoto, Yuichi Kodama, Takuro Nishikawa, Takayuki Tanabe, Yoshifumi Kawano .  Decrease of Cardiac Base Rotation in 2D Speckle Tracking Indicates Drug-induced Cardiomyopathy After Chemotherapy in Children With Cancer .  JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY39 ( 1 ) 10 - 14   2017.1Invited Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Drug-induced cardiomyopathy can be life-threatening in patients with cancer. Our objective was to explore early detection of drug-induced cardiomyopathy in children with cancer. We enrolled pediatric outpatients diagnosed with cancer between 2012 and 2013. In addition, we recruited pediatric outpatients in good general condition without cardiac disease or cancer, as controls. We measured the serum levels of biomarkers and performed chest radiography, electrocardiography, and ultrasound cardiography (UCG). We analyzed left ventricular (LV) torsion and torsion-related parameters using 2-dimensional (2D) speckle tracking on UCG. In total, 35 pediatric patients were enrolled. All patients showed negative findings for plasma troponin T, radiography, and electrocardiography. During 2D speckle tracking, 9 patients were excluded due to inappropriate dynamic echo images. We compared UCG findings between 26 patients and 16 controls. Although there was no difference in ejection fraction between patients and controls, peak LV torsion tended to be lower in patients than in controls, and the absolute basal rotation value at the timing of peak LV torsion was significantly lower in patients than in controls. In conclusion, a decrease of basal rotation in 2D speckle tracking might indicate the initial changes leading to myocardial disorder after chemotherapy.

    DOI: 10.1097/MPH.0000000000000683

    Web of Science

    Scopus

    PubMed

  • Yasuhiro Okamoto, Yuichi Kodama, Takuro Nishikawa, Almitra Rindiarti, Takayuki Tanabe, Shunsuke Nakagawa, Takako Yoshioka, Koji Takumi, Tatsuru Kaji, Yoshifumi Kawano .  Persistent positive metaiodobenzylguanidine scans after autologous peripheral blood stem cell transplantation may indicate maturation of stage 4 neuroblastoma .  PEDIATRIC HEMATOLOGY AND ONCOLOGY34 ( 3 ) 157 - 164   2017

     More details

    Publisher:TAYLOR & FRANCIS INC  

    Metaiodobenzylguanidine (MIBG) scans are sensitive testing tools for neuroblastoma. Persistent positive MIBG scans in patients with stage 3 neuroblastoma have previously been found to indicate maturation rather than regression. We assessed the significance of this finding in stage 4 neuroblastoma in the present study. Fifteen consecutive pediatric patients with stage 4 neuroblastoma treated between 2004 and 2014 at the Kagoshima University Hospital were retrospectively examined. Treatment involved a combination of multiagent chemotherapy, resection, autologous peripheral blood stem cell transplantation (PBSCT), radiotherapy, and maintenance therapy with retinoic acid. The MIBG uptake in each patient during treatment was assessed using a Curie score. The 5-year event-free and overall survival rates in 15 patients were 38.9% and 58.7%, respectively. Four patients with persistent positive MIBG scans who underwent autologous PBSCT but experienced decreased I-123-MIBG uptake during the clinical course survived without progression, and their event-free survival (EFS) was significantly superior to that of patients who showed negative MIBG scans after PBSCT (5-year EFS rate: 18.2%, p = 0.0176). Therefore, persistent positive MIBG scans with gradually decreased uptake after PBSCT do not always indicate neuroblastoma progression, and may instead indicate tumor maturation in some selected cases, if not all cases, of stage 4 neuroblastoma.

    DOI: 10.1080/08880018.2017.1348414

    Web of Science

    Scopus

    PubMed

  • Maruyama S, Okamoto Y, Toyoshima M, Hanaya R, Kawano Y .  Immunoglobulin A deficiency following treatment with lamotrigine. .  Brain & development38 ( 10 ) 947 - 949   2016.11Immunoglobulin A deficiency following treatment with lamotrigine.

  • Shiokawa N, Okamoto Y, Kodama Y, Nishikawa T, Tanabe T, Mukai M, Yoshioka T, Kawano Y .  Conservative treatment of massive hemothorax in a girl with neuroblastoma. .  Pediatrics international : official journal of the Japan Pediatric Society58 ( 10 ) 1090 - 1092   2016.10Conservative treatment of massive hemothorax in a girl with neuroblastoma.

     More details

  • Wakiguchi H, Okamoto Y, Matsunaga M, Kodama Y, Miyazono A, Seki S, Ikeda N, Kawano Y .  Multiple Renal and Splenic Lesions in Cat Scratch Disease. .  Japanese journal of infectious diseases69 ( 5 ) 424 - 5   2016.9Multiple Renal and Splenic Lesions in Cat Scratch Disease.

  • Miyazono A, Okamoto Y, Nagasako H, Hamasaki Y, Shishido S, Yoshioka T, Kawano Y .  Multifocal Epstein-Barr Virus-Negative Posttransplantation Lymphoproliferative Disorder Treated With Reduction of Immunosuppression. .  American journal of kidney diseases : the official journal of the National Kidney Foundation68 ( 3 ) 469 - 72   2016.9Multifocal Epstein-Barr Virus-Negative Posttransplantation Lymphoproliferative Disorder Treated With Reduction of Immunosuppression.

  • Pornpun P, Okamoto Y, Nishikawa T, Kodama Y, Yamaki Y, Kurauchi K, Tanabe T, Nakagawa S, Shinkoda Y, Imuta N, Kawano Y. .  Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma. .  Pediatric Blood & Cancer   2016.8Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Koh K, Ogawa C, Okamoto Y, Kudo K, Inagaki J, Morimoto T, Mizukami H, Ecstein-Fraisse E, Kikuta A .  Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan. .  International journal of hematology104 ( 2 ) 245 - 55   2016.8Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.

  • Saito A, Okamoto Y, Seki Y, Matsunaga M, Nakagawa S, Kodama Y, Nishikawa T, Tanabe T, Kawano Y .  DIC Complicating APL Successfully Treated With Recombinant Thrombomodulin Alfa. .  Journal of pediatric hematology/oncology38 ( 6 ) e189 - 90   2016.8DIC Complicating APL Successfully Treated With Recombinant Thrombomodulin Alfa.

  • Nakagawa S, Shinkoda Y, Hazeki D, Imamura M, Okamoto Y, Kawakami K, Kawano Y .  Central diabetes insipidus as a very late relapse limited to the pituitary stalk in Langerhans cell histiocytosis. .  Journal of pediatric endocrinology & metabolism : JPEM29 ( 7 ) 873 - 8   2016.7Central diabetes insipidus as a very late relapse limited to the pituitary stalk in Langerhans cell histiocytosis.

     More details

  • Kodama Y, Okamoto Y, Tanabe T, Nishikawa T, Abematsu T, Nakagawa S, Kurauchi K, Shinkoda Y, Ikeda N, Seki S, Wakiguchi H, Miyazono A, Kawano Y .  Central venous catheter-related blood stream infection with pyomyositis due to Stenotrophomonas maltophilia after allogeneic bone marrow transplantation in a patient with aplastic anemia. .  Pediatric transplantation20 ( 2 ) 329 - 32   2016.3Central venous catheter-related blood stream infection with pyomyositis due to Stenotrophomonas maltophilia after allogeneic bone marrow transplantation in a patient with aplastic anemia.

     More details

  • 2. Okamoto Y, Koga Y, Inagaki J, Ozono S, Ueda K, Shimoura M, Itonaga N, Shinkoda Y, Moritake H, Nomura Y, Nakayama H, Hotta N, Hidaka Y, Shimonodan H, Suga N, Tanabe T, Nakashima K, Fukano R, Kawano Y .  Effective VCR/DEX pulse maintenance therapy in the KYCCSG ALL-02 protocol for pediatric acute lymphoblastic leukemia. .  Int J Hematol103 ( 2 ) 202 - 209   2016.2Effective VCR/DEX pulse maintenance therapy in the KYCCSG ALL-02 protocol for pediatric acute lymphoblastic leukemia.Reviewed

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • Okamoto Y, Koga Y, Inagaki J, Ozono S, Ueda K, Shimoura M, Itonaga N, Shinkoda Y, Moritake H, Nomura Y, Nakayama H, Hotta N, Hidaka Y, Shimonodan H, Suga N, Tanabe T, Nakashima K, Fukano R, Kawano Y .  Effective VCR/DEX pulse maintenance therapy in the KYCCSG ALL-02 protocol for pediatric acute lymphoblastic leukemia. .  International journal of hematology103 ( 2 ) 202 - 9   2016.2Effective VCR/DEX pulse maintenance therapy in the KYCCSG ALL-02 protocol for pediatric acute lymphoblastic leukemia.

  • Watanabe E, Nishikawa T, Ikawa K, Yamaguchi H, Abematsu T, Nakagawa S, Kurauchi K, Kodama Y, Tanabe T, Shinkoda Y, Matsumoto K, Okamoto Y, Takeda Y, Kawano Y .  Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients. .  International journal of hematology102 ( 5 ) 611 - 6   2015.11Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.

  • Ishida H, Adachi S, Hasegawa D, Okamoto Y, Goto H, Inagaki J, Inoue M, Koh K, Yabe H, Kawa K, Kato K, Atsuta Y, Kudo K .  Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents. .  Pediatric blood & cancer62 ( 5 ) 883 - 9   2015.5Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents.

     More details

  • Wang R, Yoshida K, Toki T, Sawada T, Uechi T, Okuno Y, Sato-Otsubo A, Kudo K, Kamimaki I, Kanezaki R, Shiraishi Y, Chiba K, Tanaka H, Terui K, Sato T, Iribe Y, Ohga S, Kuramitsu M, Hamaguchi I, Ohara A, Hara J, Goi K, Matsubara K, Koike K, Ishiguro A, Okamoto Y, Watanabe K, Kanno H, Kojima S, Miyano S, Kenmochi N, Ogawa S, Ito E .  Loss of function mutations in RPL27 and RPS27 identified by whole-exome sequencing in Diamond-Blackfan anaemia. .  British journal of haematology168 ( 6 ) 854 - 64   2015.3Loss of function mutations in RPL27 and RPS27 identified by whole-exome sequencing in Diamond-Blackfan anaemia.

     More details

  • Kato K, Kato M, Hasegawa D, Kawasaki H, Ishida H, Okamoto Y, Koh K, Inoue M, Inagaki J, Kato K, Sakamaki H, Yabe H, Kawa K, Suzuki R, Atsuta Y .  Comparison of transplantation with reduced and myeloablative conditioning for children with acute lymphoblastic leukemia. .  Blood125 ( 8 ) 1352 - 4   2015.2Comparison of transplantation with reduced and myeloablative conditioning for children with acute lymphoblastic leukemia.

  • Nishikawa T, Miyahara E, Kurauchi K, Watanabe E, Ikawa K, Asaba K, Tanabe T, Okamoto Y, Kawano Y .  Mechanisms of Fatal Cardiotoxicity following High-Dose Cyclophosphamide Therapy and a Method for Its Prevention. .  PloS one10 ( 6 ) e0131394   2015Mechanisms of Fatal Cardiotoxicity following High-Dose Cyclophosphamide Therapy and a Method for Its Prevention.

  • Nishikawa T, Okamoto Y, Maruyama S, Tanabe T, Kurauchi K, Kodama Y, Nakagawa S, Shinkoda Y, Kawano Y .  Acute encephalomyelitis complicated with severe neurological sequelae after intrathecal administration of methotrexate in a patient with acute lymphoblastic leukemia. .  [Rinsho ketsueki] The Japanese journal of clinical hematology55 ( 11 ) 2306 - 10   2014.11Acute encephalomyelitis complicated with severe neurological sequelae after intrathecal administration of methotrexate in a patient with acute lymphoblastic leukemia.

     More details

  • Kobayashi R, Yabe H, Kikuchi A, Kudo K, Yoshida N, Watanabe K, Muramatsu H, Takahashi Y, Inoue M, Koh K, Inagaki J, Okamoto Y, Sakamaki H, Kawa K, Kato K, Suzuki R, Kojima S .  Bloodstream infection after stem cell transplantation in children with idiopathic aplastic anemia. .  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation20 ( 8 ) 1145 - 9   2014.8Bloodstream infection after stem cell transplantation in children with idiopathic aplastic anemia.

  • Moritake H, Kamimura S, Nunoi H, Nakayama H, Suminoe A, Inada H, Inagaki J, Yanai F, Okamoto Y, Shinkoda Y, Shimomura M, Itonaga N, Hotta N, Hidaka Y, Ohara O, Yanagimachi M, Nakajima N, Okamura J, Kawano Y .  Clinical characteristics and genetic analysis of childhood acute lymphoblastic leukemia with hemophagocytic lymphohistiocytosis: a Japanese retrospective study by the Kyushu-Yamaguchi Children's Cancer Study Group. .  International journal of hematology100 ( 1 ) 70 - 8   2014.7Clinical characteristics and genetic analysis of childhood acute lymphoblastic leukemia with hemophagocytic lymphohistiocytosis: a Japanese retrospective study by the Kyushu-Yamaguchi Children's Cancer Study Group.

  • Kodama Y, Okamoto Y, Shinkoda Y, Tanabe T, Nishikawa T, Yamaki Y, Kurauchi K, Kawano Y .  Bone marrow transplant for a girl with bone marrow failure and cerebral palsy. .  Pediatrics international : official journal of the Japan Pediatric Society56 ( 3 ) 424 - 6   2014.6Bone marrow transplant for a girl with bone marrow failure and cerebral palsy.

     More details

  • Okamoto Y, Nagatoshi Y, Kosaka Y, Kikuchi A, Kato S, Kigasawa H, Horikoshi Y, Oda M, Kaneda M, Mori T, Mugishima H, Tsuchida M, Taniguchi S, Kawano Y .  Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. .  Pediatric transplantation18 ( 3 ) 294 - 301   2014.5Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children.

     More details

  • Miyahara E, Nishikawa T, Takeuchi T, Yasuda K, Okamoto Y, Kawano Y, Horiuchi M .  Effect of myeloperoxidase inhibition on gene expression profiles in HL-60 cells exposed to 1,2,4,-benzenetriol. .  Toxicology317   50 - 7   2014.3Effect of myeloperoxidase inhibition on gene expression profiles in HL-60 cells exposed to 1,2,4,-benzenetriol.

  • Moritake H, Kamimura S, Nunoi H, Nakayama H, Suminoe A, Inada H, Inagaki J, Yanai F, Okamoto Y, Shinkoda Y, Shimomura M, Itonaga N, Hotta N, Hidaka Y, Ohara O, Yanagimachi M, Nakajima N, Okamura J, Kawano Y. .  Clinical characteristics and genetic analysis of childhood acute lymphoblastic leukemia with hemophagocytic lymphohistiocytosis: a Japanese retrospective study by the Kyushu-Yamaguchi Children’s Cancer Study Group. .  Int J Hematol ( 100 ) 70 - 78   2014.1Clinical characteristics and genetic analysis of childhood acute lymphoblastic leukemia with hemophagocytic lymphohistiocytosis: a Japanese retrospective study by the Kyushu-Yamaguchi Children’s Cancer Study Group.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Miyahara E, Nishikawa T, Takeuchi T, Yasuda K, Okamoto Y, Kawano Y, Horiuchi M. .  Effect of myeloperoxidase inhibition on gene expression profiles in HL-60 cells exposed to 1, 2, 4,-benzenetriol. .  Toxicology ( 57 ) 50 - 57   2014.1Effect of myeloperoxidase inhibition on gene expression profiles in HL-60 cells exposed to 1, 2, 4,-benzenetriol. Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Okamoto Y, Nagatoshi Y, Kosaka Y, Kikuchi A, Kato S, Kigasawa H, Horikoshi Y, Oda M, Kaneda M, Mori T, Mugishima H, Tsuchida M, Taniguchi S, Kawano Y. .  Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. .  Pediatr Transplant18   294 - 301   2014.1Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Hyakuna N, Shimomura Y, Watanabe A, Taga T, Kikuta A, Matsushita T, Kogawa K, Kawakami C, Horikoshi Y, Iwai T, Okamoto Y, Tsurusawa M, Asami K, Japanese Childhood Cancer and Leukemia Study Group (JCCLSG). .  Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. .  Journal of pediatric hematology/oncology36 ( 1 ) 22 - 9   2014.1Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.

  • Kato M, Takahashi Y, Tomizawa D, Okamoto Y, Inagaki J, Koh K, Ogawa A, Okada K, Cho Y, Takita J, Goto H, Sakamaki H, Yabe H, Kawa K, Suzuki R, Kudo K, Kato K .  Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia. .  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation19 ( 12 ) 1690 - 4   2013.12Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia.

  • Chen J, Lee V, Luo CJ, Chiang AK, Hongeng S, Tan PL, Tan AM, Sanpakit K, Li CF, Lee AC, Chua HC, Okamoto Y .  Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group. .  British journal of haematology162 ( 3 ) 383 - 91   2013.8Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group.

     More details

  • Kodama Y, Okamoto Y, Nishi J, Hashiguchi S, Yamaki Y, Kurauchi K, Tanabe T, Shinkoda Y, Nishikawa T, Suda Y, Kawano Y .  Ramsay Hunt syndrome in a girl with acute lymphoblastic leukemia during maintenance therapy. .  Journal of pediatric hematology/oncology35 ( 5 ) e224 - 5   2013.7Ramsay Hunt syndrome in a girl with acute lymphoblastic leukemia during maintenance therapy.

  • Kodama Y, Okamoto Y, Nishi J, Hashiguchi S, Yamaki Y, Kurauchi K, Tanabe T, Shinkoda Y, Nishikawa T, Suda Y, Kawano Y .  Ramsay Hunt Syndrome in a Girl With Acute Lymphoblastic Leukemia During Maintenance Therapy. .  J Pediatr Hematol Oncol ( 35 ) 224 - 225   2013.1Ramsay Hunt Syndrome in a Girl With Acute Lymphoblastic Leukemia During Maintenance Therapy.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Chen J, Lee V, Luo CJ, Kwok A, Chiang S, Hongeng S, Tan PL, Tan AM, Sanpakit K, Li CF, Lee AC, Chua HC, Okamoto Y .  Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group. .  Br J Heamatol ( 162 ) 383 - 391   2013.1Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Kodama Y, Okamoto Y, Hashiguchi T, Shinkoda Y, Nishikawa T, Tanabe T, Kawano Y .  Vascular endothelial growth factor corrected for platelet count and hematocrit is associated with the clinical course of aplastic anemia in children. .  International journal of hematology95 ( 5 ) 494 - 9   2012.5Vascular endothelial growth factor corrected for platelet count and hematocrit is associated with the clinical course of aplastic anemia in children.

  • Kodama Y, Okamoto Y, Hashiguchi T, Shinkoda Y, Nishikawa T, Tanabe T, Kawano Y. .  Vascular endothelial growth factor corrected for platelet count and hematocrit is associated with the clinical course of aplastic anemia in children. .  Int J Hematol ( 95 ) 494 - 499   2012.1Vascular endothelial growth factor corrected for platelet count and hematocrit is associated with the clinical course of aplastic anemia in children. Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nishikawa T, Miyahara E, Horiuchi M, Izumo K, Okamoto Y, Kawai Y, Kawano Y, Takeuchi T .  Benzene metabolite 1,2,4-benzenetriol induces halogenated DNA and tyrosines representing halogenative stress in the HL-60 human myeloid cell line. .  Environmental health perspectives120 ( 1 ) 62 - 7   2012.1Benzene metabolite 1,2,4-benzenetriol induces halogenated DNA and tyrosines representing halogenative stress in the HL-60 human myeloid cell line.

     More details

  • Bakhtiar Y, Yonezawa H, Bohara M, Hanaya R, Okamoto Y, Sugiyama K, Yoshioka T, Arita K .  Posterior fossa immature teratoma in an infant with trisomy 21: A case report and review of the literature. .  Surgical neurology international3   100   2012Posterior fossa immature teratoma in an infant with trisomy 21: A case report and review of the literature.

  • Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Kakihana Y, Goto M, Kawano Y .  Acute respiratory distress syndrome as an initial presentation of hemophagocytic lymphohistiocytosis after induction therapy for acute myeloid leukemia. .  Pediatric hematology and oncology28 ( 3 ) 244 - 8   2011.4Acute respiratory distress syndrome as an initial presentation of hemophagocytic lymphohistiocytosis after induction therapy for acute myeloid leukemia.

  • Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Kakihana Y, Goto M, Kawano Y .  Acute respiratory distress syndrome as an initial presentation of hemophagocytic lymphohistiocytosis after induction therapy for acute myeloid leukemia. .  Pediatric Hematology Oncology3   244 - 248   2011.2Acute respiratory distress syndrome as an initial presentation of hemophagocytic lymphohistiocytosis after induction therapy for acute myeloid leukemia.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nishikawa T, Izumo K, Miyahara E, Horiuchi M, Okamoto Y, Kawano Y, Takeuchi T .  Benzene induces cytotoxicity without metabolic activation .  Journal of Occupational Health53 ( 2 ) 84 - 92   2011.2Benzene induces cytotoxicity without metabolic activationReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nishikawa T, Izumo K, Miyahara E, Horiuchi M, Okamoto Y, Kawano Y, Takeuchi T .  Benzene induces cytotoxicity without metabolic activation. .  Journal of occupational health53 ( 2 ) 84 - 92   2011Benzene induces cytotoxicity without metabolic activation.

     More details

  • Okamoto Y, Kodama Y, Nishikawa T, Yamaki Y, Mougi H, Masamoto I, Tanabe T, Shinkoda Y, Kawano Y .  Successful Bone Marrow Transplantation for Children with Aplastic Anemia based on a Best-Available Evidence Strategy .  Pediatric Transplantation14   980 - 985   2010.12Successful Bone Marrow Transplantation for Children with Aplastic Anemia based on a Best-Available Evidence StrategyReviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Okamoto Y, Kodama Y, Nishikawa T, Yamaki Y, Mougi H, Masamoto I, Tanabe T, Shinkoda Y, Kawano Y .  Successful bone marrow transplantation for children with aplastic anemia based on a best-available evidence strategy. .  Pediatric transplantation14 ( 8 ) 980 - 5   2010.12Successful bone marrow transplantation for children with aplastic anemia based on a best-available evidence strategy.

  • Nishikawa T, Okamoto Y, Kodama Y, Tanabe T, Shinkoda Y, Kawano Y .  Serum derivative of reactive oxygen metabolites (d-ROMs) in pediatric hemato-oncological patients with neutropenic fever. .  Pediatric blood & cancer55 ( 1 ) 91 - 4   2010.7Serum derivative of reactive oxygen metabolites (d-ROMs) in pediatric hemato-oncological patients with neutropenic fever.

     More details

  • Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Higashi M, Hirano H, Arita K, Kawano Y. .  Unexpectedly High AUC Levels in a Child who Received Intravenous Busulfan prior to Stem Cell Transplantation. .  Bone Marrow Transplantation45   602 - 604   2010.5Unexpectedly High AUC Levels in a Child who Received Intravenous Busulfan prior to Stem Cell Transplantation.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Ueno K, Nagasako H, Ueno M, Nerome Y, Eguchi T, Okamoto Y, Nomura Y, Kawano Y .  Large intracardiac thrombus in a child with refractory nephrotic syndrome. .  Pediatrics international : official journal of the Japan Pediatric Society52 ( 1 ) e51 - 3   2010.2Large intracardiac thrombus in a child with refractory nephrotic syndrome.

     More details

    Language:English  

    DOI: 10.1111/j.1442-200X.2009.02991.x

    PubMed

  • Nishikawa T, Okamoto Y, Kodama Y, Tanabe T, Shinkoda Y, Kawano Y .  Serum derivative of reactive oxygen metabolites (d-ROMs) in pediatric hemato-oncological patients with neutropenic fever. .  Pediatr Blood Cancer55   91 - 94   2010.1Serum derivative of reactive oxygen metabolites (d-ROMs) in pediatric hemato-oncological patients with neutropenic fever.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Ueno K, Nagasako H, Ueno M, Nerome Y, Eguchi T, Okamoto Y, Nomura Y, Kawano Y. .  Large intracardiac thrombus in a child with refractory nephrotic syndrome. .  Pediatric International52   51 - 53   2010.1Large intracardiac thrombus in a child with refractory nephrotic syndrome. Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Kodama Y, Okamoto Y, Ijichi O, Shinkoda Y, Nishikawa T, Tanabe T, Yoshioka T, Tashiro Y, Mougi H, Kawano Y .  Continued complete remission without systemic therapy for isolated testicular relapse after bone marrow transplantation in a boy with acute lymphoblastic leukemia. .  Pediatric transplantation13 ( 6 ) 769 - 72   2009.9Continued complete remission without systemic therapy for isolated testicular relapse after bone marrow transplantation in a boy with acute lymphoblastic leukemia.

  • Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Tsuru Y, Kawano Y .  Calcineurin-inhibitor-induced pain syndrome after a second allogeneic bone marrow transplantation for a child with aplastic anemia. .  Pediatric transplantation13 ( 5 ) 641 - 4   2009.8Calcineurin-inhibitor-induced pain syndrome after a second allogeneic bone marrow transplantation for a child with aplastic anemia.

  • Nishikawa T, Okamoto Y, Tanabe T, Kodama Y, Shinkoda Y, Kawano Y .  Critical Illness Polyneuropathy after Bacillus cereus Sepsis in Acute Lymphoblastic Leukemia. .  Internal Medicine48   1175 - 1177   2009.7Critical Illness Polyneuropathy after Bacillus cereus Sepsis in Acute Lymphoblastic Leukemia.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Kodama Y, Okamoto Y, Ijichi O, Shinkoda Y, Nishikawa T, Tanabe T, Yoshioka T, Tashiro T, Mougi H, Kawano Y .  Continued complete remission without systemic therapy for isolated testicular relapse after bone marrow transplantation in a boy with acute lymphoblastic leukemia. .  Pediatric Transplantation13   769 - 772   2009.6Continued complete remission without systemic therapy for isolated testicular relapse after bone marrow transplantation in a boy with acute lymphoblastic leukemia. Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Okamoto Y, Watanabe T, Watanabe H, Onishi T, Kawano Y .  Double apheresis of peripheral blood stem cells in a single day in children mobilized by granulocyte colony-stimulating factor for transplantation. .  Pediatric transplantation13 ( 4 ) 440 - 3   2009.6Double apheresis of peripheral blood stem cells in a single day in children mobilized by granulocyte colony-stimulating factor for transplantation.

  • Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Tsuru Y, Kawano Y. .  Calcineurin-inhibitor-induced pain syndrome after a second allogeneic bone marrow transplantation for a child with aplastic anemia. .  Pediatric Transplant13   641 - 644   2009.5Calcineurin-inhibitor-induced pain syndrome after a second allogeneic bone marrow transplantation for a child with aplastic anemia. Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Okamoto Y, Watanabe T, Watanabe H, Onishi T, Kawano Y .  Double apheresis of peripheral blood stem cells in a single day in children mobilized by granulocyte colony-stimulating factor for transplantation. .  Pediatr Transplantation13   440 - 443   2009.1Double apheresis of peripheral blood stem cells in a single day in children mobilized by granulocyte colony-stimulating factor for transplantation.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nishikawa T, Okamoto Y, Tanabe T, Kodama Y, Shinkoda Y, Kawano Y .  Critical illness polyneuropathy after Bacillus cereus sepsis in acute lymphoblastic leukemia. .  Internal medicine (Tokyo, Japan)48 ( 13 ) 1175 - 7   2009Critical illness polyneuropathy after Bacillus cereus sepsis in acute lymphoblastic leukemia.

  • Nishikawa T, Kawakami K, Kumamoto T, Tonooka S, Abe A, Hayasaka K, Okamoto Y, Kawano Y .  Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. .  Journal of pediatric hematology/oncology30 ( 7 ) 519 - 21   2008.7Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.

  • Watanabe H, Watanabe T, Kaneko M, Suzuya H, Onishi T, Okamoto Y, Miyake H, Yasuo K, Hirose T, Kagami S .  Treatment of unresectable malignant rhabdoid tumor of the orbit with tandem high-dose chemotherapy and gamma-knife radiosurgery. .  Pediatric blood & cancer47 ( 6 ) 846 - 50   2006.11Treatment of unresectable malignant rhabdoid tumor of the orbit with tandem high-dose chemotherapy and gamma-knife radiosurgery.

     More details

  • Shinkoda Y, Ijichi O, Tanabe T, Nishikawa T, Manago K, Ishikawa S, Kodama Y, Okamoto Y, Ikarimoto N, Kawano Y .  Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine. .  Pediatric transplantation10 ( 7 ) 822 - 5   2006.11Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine.

  • Shinkoda Y, Tanaka S, Ijichi O, Yoshikawa H, Nonaka Y, Tanabe T, Nishikawa T, Ishikawa S, Okamoto Y, Kaji T, Tahara H, Takamatsu H, Nagata K, Kawano Y .  Successful treatment of an endodermal sinus tumor of the vagina by chemotherapy alone: a rare case of an infant diagnosed by pathological examination of discharged tumor fragment. .  Pediatric hematology and oncology23 ( 7 ) 563 - 9   2006.10Successful treatment of an endodermal sinus tumor of the vagina by chemotherapy alone: a rare case of an infant diagnosed by pathological examination of discharged tumor fragment.

  • Ijichi O, Ishikawa S, Shinkoda Y, Tanabe T, Okamoto Y, Takamatsu H, Inomata Y, Kawano Y .  Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan. .  Pediatric transplantation10 ( 5 ) 635 - 8   2006.8Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan.

  • Nakagawa R, Watanabe T, Kawano Y, Kanai S, Suzuya H, Kaneko M, Watanabe H, Okamoto Y, Kuroda Y, Nakayama T, Chugoku-Shikoku Cord Blood Bank. .  Analysis of maternal and neonatal factors that influence the nucleated and CD34+ cell yield for cord blood banking. .  Transfusion44 ( 2 ) 262 - 7   2004.2Analysis of maternal and neonatal factors that influence the nucleated and CD34+ cell yield for cord blood banking.

     More details

    Language:English  

    DOI: 10.1111/j.1537-2995.2004.00645.x

    PubMed

  • Kawano Y, Lee CL, Watanabe T, Abe T, Suzuya H, Okamoto Y, Makimoto A, Nakagawa R, Watanabe H, Takaue Y .  Cryopreservation of mobilized blood stem cells at a higher cell concentration without the use of a programmed freezer. .  Annals of hematology83 ( 1 ) 50 - 4   2004.1Cryopreservation of mobilized blood stem cells at a higher cell concentration without the use of a programmed freezer.

  • Loyd MR, Okamoto Y, Randall MS, Ney PA .  Role of AP1/NFE2 binding sites in endogenous alpha-globin gene transcription. .  Blood102 ( 12 ) 4223 - 8   2003.12Role of AP1/NFE2 binding sites in endogenous alpha-globin gene transcription.

  • Kaneko M, Watanabe T, Watanabe H, Kimura M, Suzuya H, Okamoto Y, Nakagawa R, Kuroda Y .  Successful unrelated cord blood transplantation in an infant with Wiskott-Aldrich syndrome following recurrent cytomegalovirus disease. .  International journal of hematology78 ( 5 ) 457 - 60   2003.12Successful unrelated cord blood transplantation in an infant with Wiskott-Aldrich syndrome following recurrent cytomegalovirus disease.

     More details

  • Okamoto Y, Mathew S, Daw NC, Neel MD, McCarville MB, Dome JS, Hill DA .  Giant cell tumor of bone with pulmonary metastases. .  Medical and pediatric oncology41 ( 5 ) 454 - 9   2003.11Giant cell tumor of bone with pulmonary metastases.

     More details

  • Okamoto Y, Ribeiro RC, Srivastava DK, Shenep JL, Pui CH, Razzouk BI .  Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. .  Journal of pediatric hematology/oncology25 ( 9 ) 696 - 703   2003.9Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia.

  • Kageji T, Nagahiro S, Horiguchi H, Watanabe T, Suzuya H, Okamoto Y, Kuroda Y .  Successful high-dose chemotherapy for widespread neuroaxis dissemination of an optico-hypothalamic juvenile pilocytic astrocytoma in an infant: a case report. .  Journal of neuro-oncology62 ( 3 ) 281 - 7   2003.5Successful high-dose chemotherapy for widespread neuroaxis dissemination of an optico-hypothalamic juvenile pilocytic astrocytoma in an infant: a case report.

     More details

  • Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH .  The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. .  Blood101 ( 5 ) 1818 - 26   2003.3The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis.

  • Okamoto Y, Ribeiro RC, Tong X, Srivastava DK, Shenep JL, Pui CH, Rubnitz JE, Razzouk BI .  Clinical features and complications of viridans streptococcal sepsis in pediatric patients receiving chemotherapy for acute myeloid leukemia. .  J Pediatr Hematol Oncol25   696 - 703   2003.1Clinical features and complications of viridans streptococcal sepsis in pediatric patients receiving chemotherapy for acute myeloid leukemia.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Okamoto Y, Mathew S, Daw NC, Neel MN, McCarville MB, Dome JS, Hill A. .  Giant Cell Tumor of Bone with Pulmonary Metastases. .  Med Pediatr Oncol 41   454 - 459   2003.1Giant Cell Tumor of Bone with Pulmonary Metastases.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Nagatoshi Y, Kawano Y, Watanabe T, Abe T, Okamoto Y, Kuroda Y, Takaue Y, Okamura J .  Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population. .  Pediatric transplantation6 ( 4 ) 319 - 26   2002.8Hematopoietic and immune recovery after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation in a pediatric population.

  • Okamoto Y, Kawano Y, Takaue Y, Watanabe T, Kato T, Shimosaka A, Kuroda Y .  Serum Thrombopoietin Levels in Patients Receiving High-Dose Chemotherapy with Support of Purified Peripheral Blood CD34+ Cells. .  Cancer Res57   5037 - 5040   1997.1Serum Thrombopoietin Levels in Patients Receiving High-Dose Chemotherapy with Support of Purified Peripheral Blood CD34+ Cells.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Okamoto Y, Takaue Y, Saito S, Shimizu T, Suzue T, Abe T, Sato J, Hirao A, Watanabe T, Kawano Y, Kuroda Y .  Toxicities associated with cryopreserved and thawed peripheral blood stem cell autografts in children with active cancer. .  Transfusion33   578 - 581   1993.1Toxicities associated with cryopreserved and thawed peripheral blood stem cell autografts in children with active cancer.Reviewed

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

▼display all

Books

MISC

  • 【抗菌薬の「なぜ?」に答える】発熱性好中球減少症時の抗微生物薬

    岡本 康裕

    小児内科   52 ( 10 )   1499 - 1504   2020.10

     More details

    Publisher:(株)東京医学社  

    <Key Points>(1)発熱性好中球減少症(febrile neutropenia:FN)は、重篤となるリスクが高い緊急疾患である。(2)敗血症のリスクや徴候がある場合には、30分以内に、そうでなくても1時間以内に抗菌薬を投与する。(3)緊急のFNに対応できるインフラを整備することが重要である。(4)FNの初期治療のエビデンスは高いが、治療の変更、中止基準などのエビデンスは高くない。(著者抄録)

  • ギルテリチニブで寛解に達したFLT3-ITD,NUP98-NSD1共発現の急性骨髄性白血病8歳男児

    西川拓朗, あべ松貴成, 中村達郎, 中川俊輔, 児玉祐一, 岡本康裕, 河野嘉文

    日本血液学会学術集会抄録(Web)   82nd   2020

     More details

  • 診断に難渋した前腕原発spindle cell sarcomaの1例

    井上 一利, 西川 拓朗, 平木 翼, 佐々木 裕美, 義岡 孝子, 中川 俊輔, 児玉 祐一, 岡本 康裕, 谷本 昭英, 河野 嘉文

    日本小児血液・がん学会雑誌   56 ( 2 )   212 - 215   2019.9

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

    1歳9ヵ月の男児。左前腕部の腫脹に気付き紹介医を受診、MRI検査で6cm弱の充実性腫瘤を認め当科紹介となった。転移巣なく、生検術を行った。当初、生検材料の病理検索ではinfantile fibrosarcomaを考えたが、中央病理診断ではmyofibromaが疑われた。臨床的な判断に基づいて、vincristine、actinomycine、ifosfamideによる化学療法を開始したが、腫瘍径は変化なかった。中央病理診断の結果と治療反応から、化学療法は開始2ヵ月で中止した。中止3ヵ月後より腫瘤が増大し、中止4ヵ月後に腫瘍辺縁切除術を行った。この際の病理診断はspindle cell sarcoma、unclassifiedであった。局所照射、vincristine、ifosfamide、doxorubicinによる化学療法を3クール行い治療終了した。病理診断が臨床経過に合わない場合は、再度検体を採取し、病理検査を行うことを考慮する。(著者抄録)

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J06030&link_issn=&doc_id=20191122310021&doc_link_id=%2Fex9syoga%2F2019%2F005602%2F021%2F0212-0215%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fex9syoga%2F2019%2F005602%2F021%2F0212-0215%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 異なる経過をたどった小児大腸癌の2例

    杉田 光士郎, 川野 孝文, 森口 智江, 大西 峻, 池江 隆正, 児玉 祐一, 西川 拓朗, 岡本 康裕, 加治 建, 家入 里志

    日本小児外科学会雑誌   55 ( 5 )   968 - 976   2019.8

     More details

    Language:Japanese   Publisher:(NPO)日本小児外科学会  

    【症例1】14歳男児。主訴は食欲不振・るい痩で、腹部造影CT検査で腹部腫瘤を指摘され紹介となった。下行結腸に完全閉塞を伴う全周性隆起性病変とS状結腸以下に多発polypを認めた。左半結腸切除、D2+傍大動脈リンパ節郭清を行い、stage IVの診断であった。術後化学療法を行ったが、診断から1年後に死亡した。【症例2】10歳男児。主訴は血便・腹痛、腹部造影CT検査で腸重積の診断となり紹介となった。年齢と部位より器質的疾患の存在を考え、緊急で審査腹腔鏡を施行した。横行結腸脾彎曲部の腸重積部分に腫瘤性病変を認め、悪性リンパ腫と判断し局所切除を行った。病理診断は粘液癌で、腹腔鏡下左半結腸切除とD3リンパ節郭清を追加した。Stage IIIbの診断で化学療法を施行し、術後2年無再発生存中である。【結語】小児大腸癌は極めて稀であるが、年長時の遷延する消化器症状では鑑別する必要がある。(著者抄録)

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J01113&link_issn=&doc_id=20190903070010&doc_link_id=10.11164%2Fjjsps.55.5_968&url=https%3A%2F%2Fdoi.org%2F10.11164%2Fjjsps.55.5_968&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 【Down症候群の医療管理】医療管理 Down症候群の急性リンパ性白血病

    岡本 康裕

    小児内科   51 ( 6 )   813 - 816   2019.6

     More details

    Publisher:(株)東京医学社  

    <Key Points>(1)Down症候群では、急性リンパ性白血病の発症頻度が20倍高い。(2)CRLF2異常を伴い、治療抵抗性の急性リンパ性白血病が多い。(3)治療による感染合併症と粘膜傷害が多く、厳重な管理が必要である。(4)微小残存病変を評価して、リスクに応じた治療を行う必要がある。(著者抄録)

  • Hematopoietic Stem Cell Transplantation in Children with Refractory Acute Lymphoblastic Leukemia

    Yasuhiro Okamoto, Yozo Nakazawa, Masami Inoue, Kenichiro Watanabe, Hiroaki Goto, Nao Yoshida, Maiko Noguchi, Atsushi Kikuta, Koji Kato, Yoshiko Hashii, Yoshiko Atsuta, Motohiro Kato

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-111301

    Web of Science

  • ダウン症候群に合併した急性リンパ性白血病

    岡本 康裕

    日本小児血液・がん学会雑誌   55 ( 3 )   217 - 222   2018.10

     More details

    Publisher:(一社)日本小児血液・がん学会  

    ダウン症候群(DS)において急性リンパ性白血病(ALL)の発症する頻度は、非DS-ALLの20倍とされる。21番染色体上にあるHMGN1の働きでリンパ系の増殖が起こり、さらにP2RY8-CRLF2融合などによるCRLF2の過剰発現により、JAK-STATの活性化が起こり、ALL細胞が増殖するという機序が考えられる。このCRLF2の融合はDS-ALLの50-60%に認められる。現在、CRLF2の下流のPI3KとmTORの阻害薬や、TSLPR/CRLF2抗体などが開発中で、JAK2阻害薬は第二相試験が米国で開始された。世界の研究グループからの658例を対象とした後方視的研究では、DS-ALLの8年無病生存率は64%で、非DS-ALLの81%より有意に低い。DS-ALLでは、予後良好である高二倍体やETV6-RUNX1異常などが少ないこと、予後不良のCRLF2の異常が多いこと、また粘膜障害、感染合併症などによる副作用死亡が多いために、ALLの治療成績の向上の歴史から取り残された。しかし、最近のDana-Farber癌研究所の報告では、38例と少数であるが、5年無病生存率が91%で、非DS-ALLと差がなかった。微小残存病変などによるリスクに応じた適切な治療や、適切な副作用対策を行えば、DS-ALLの治療成績が改善する可能性がある。このためDS-ALLを独立した疾患として特化した臨床研究が望まれる。DS-ALLの希少性を克服するために、シンガポール、マレーシア、台湾、香港と日本が参加する国際共同研究が2018年に始まった。微小残存病変をフローサイトメトリー法によって評価し、予後良好群では治療を軽減する。本試験によりDS-ALLに対する標準治療が確立され、さらに特異的な治療が開発されることが期待される。(著者抄録)

  • 新たに前駆B細胞急性リンパ性白血病と診断された小児と若年者に対する第II/III相試験 日本における国際多施設共同試験のプロトコル(Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan)

    Koh Katsuyoshi, Kato Motohiro, Saito Akiko M., Kada Akiko, Kawasaki Hirohide, Okamoto Yasuhiro, Imamura Toshihiko, Horibe Keizo, Manabe Atsushi

    Japanese Journal of Clinical Oncology   48 ( 7 )   684 - 691   2018.7

     More details

    Publisher:Oxford University Press  

  • 生検術でmyofibromaと診断された前腕原発spindle cell sarcoma

    井上 一利, 西川 拓朗, 中川 俊輔, 児玉 祐一, 岡本 康裕, 河野 嘉文, 佐々木 裕美, 平木 翼

    日本小児血液・がん学会雑誌   55 ( 1 )   77 - 77   2018.6

     More details

    Publisher:(一社)日本小児血液・がん学会  

  • 血液・腫瘍 急性リンパ性白血病

    岡本康裕

    小児科診療   81   471‐474   2018.4

     More details

  • 【小児の治療指針】 血液・腫瘍 急性リンパ性白血病

    岡本 康裕

    小児科診療   81 ( 増刊 )   471 - 474   2018.4

     More details

    Publisher:(株)診断と治療社  

  • 小児急性リンパ性白血病のvery late relapse例の予後 九州・山口小児がん治療研究グループ(KYCCSG)ALL 96/02研究

    野口 磨依子, 稲垣 二郎, 岡本 康裕, 古賀 友紀, 大園 秀一, 新小田 雄一, 中山 秀樹, 盛武 浩, 堀田 紀子, 糸長 伸能, 野村 優子, 下之段 秀美, 市村 卓也, 日高 靖文, 河野 嘉文

    日本小児血液・がん学会雑誌   54 ( 5 )   393 - 397   2018.4

     More details

    Publisher:(一社)日本小児血液・がん学会  

    小児急性リンパ性白血病(acute lymphoblastic leukemia:ALL)の初回治療後再発率は約20%とされ、再発時期は治療中から治療終了後早期に多いため、長期間寛解を維持した後の再発(very late relapse:VLR)症例の報告は少ない。今回、九州・山口小児がん治療研究グループ(KYCCSG)ALL-96/02プロトコールで治療を行った初発小児ALL患者のうち、治療終了後24ヵ月以降の再発例をVLRとし、その臨床的特徴と予後を検討した。KYCCSG ALL-96/02に登録・治療された357症例のうち全再発例は70例(19.6%)であった。VLRは8例(2.2%)であり、治療終了から再発までの期間の中央値は37.5ヵ月(範囲26-42ヵ月)であった。初診時リスク分類は標準リスク群が6例、高リスク群が2例で、再発部位は骨髄単独が6例、精巣単独が1例、骨髄+中枢神経が1例であった。8例すべてにおいて再寛解導入療法後第2寛解に至った。同種移植を受けた3例中1例は、移植後11ヵ月で再発し死亡した。その他の7例は再発後の観察期間57ヵ月(範囲32-92ヵ月)で寛解生存しており、VLR症例の予後は良好と考えられた。(著者抄録)

    DOI: 10.11412/jspho.54.393

  • 【小児の治療指針】血液・腫瘍 急性リンパ性白血病

    岡本 康裕

    小児科診療   81 ( 増刊 )   471 - 474   2018.4

     More details

    Publisher:(株)診断と治療社  

  • 化学療法後寛解期に食道閉鎖をきたした未分化大細胞リンパ腫

    光延拓朗, 西川拓朗, 中川俊輔, 児玉祐一, 田邊貴幸, 岡本康裕, 河野嘉文

    日本小児科学会雑誌   122 ( 2 )   357   2018.2

     More details

  • 急性リンパ性白血病治療中の低Na血症の検討

    関祐子, 岡本康裕, 宮園明典, 中川俊輔, 児玉祐一, 西川拓朗, 河野嘉文

    日本小児科学会雑誌   122 ( 2 )   356   2018.2

     More details

  • Mediastinal mature teratoma causing cardiac tamponade-A pediatric case report

    中目和彦, 山田和歌, 川野孝文, 町頭成郎, 上野健太郎, 西川拓朗, 田邊貴幸, 向井基, 義岡孝子, 義岡孝子, 岡本康裕, 加治建, 河野嘉文, 家入里志

    日本小児血液・がん学会雑誌(Web)   55 ( 5 )   2018

     More details

  • 同種骨髄移植後,病勢を制御できている骨/骨髄に再発した髄芽腫の男児例

    児玉祐一, 岡本康裕, 中川俊輔, 西川拓朗, 田邊貴幸, 河野嘉文

    日本造血細胞移植学会総会プログラム・抄録集   40th   347   2017.12

     More details

  • 小児ALLにおける移植病期が移植成績に与える影響の解析

    岡本康裕, 西川拓朗, 児玉祐一, 中川俊輔, 田邊貴幸, 河野嘉文

    日本造血細胞移植学会総会プログラム・抄録集   40th   287   2017.12

     More details

  • CCLSG ALL2004研究におけるComplete Remission症例のMRDによる解析

    堀 壽成, 山田 朋美, 下村 保人, 今井 千速, 百名 伸之, 多賀 崇, 堀越 泰雄, 山中 純子, 渡邉 健一郎, 小川 淳, 七野 浩之, 野村 恵子, 犀川 太, 西村 良成, 井上 彰子, 岡田 雅彦, 上山 潤一, 岩井 朝幸, 矢野 道広, 陳 基明, 岡本 康裕, 横田 昇平, 鶴澤 正仁, 菊田 敦, 渡辺 新, 小児がん, 白血病研究グループ

    日本小児血液・がん学会雑誌   54 ( 4 )   353 - 353   2017.10

     More details

    Publisher:(一社)日本小児血液・がん学会  

  • ALL型治療が奏功したMixed phenotype acute leukemiaの3例

    中川 俊輔, 岡本 康裕, 児玉 祐一, 西川 拓朗, 田邊 貴幸, 河野 嘉文

    日本小児血液・がん学会雑誌   54 ( 4 )   307 - 307   2017.10

     More details

    Publisher:(一社)日本小児血液・がん学会  

  • 当科における髄芽腫標準リスク群の予後

    児玉 祐一, 岡本 康裕, あべ松 貴成, 中川 俊輔, 倉内 宏一郎, 西川 拓朗, 田邊 貴幸, 新小田 雄一, 河野 嘉文

    日本小児血液・がん学会雑誌   54 ( 4 )   335 - 335   2017.10

     More details

    Publisher:(一社)日本小児血液・がん学会  

  • ダウン症に合併した急性リンパ性白血病

    岡本 康裕

    日本小児血液・がん学会雑誌   54 ( 4 )   142 - 142   2017.10

     More details

    Publisher:(一社)日本小児血液・がん学会  

  • 感染性胃腸炎罹患後に心原性ショックを呈した乳児特発性僧帽弁腱索断裂の1例

    楠田政輝, 櫨木大祐, 関祐子, 中川俊輔, 丸山慎介, 上野健太郎, 岡本康裕, 河野嘉文

    日本小児科学会雑誌   121 ( 7 )   1267   2017.7

     More details

  • 大動脈弓離断複合術後にWest症候群を発症し,ACTH療法後に急性呼吸循環不全を来した乳児例

    楠田政輝, 櫨木大祐, 関祐子, 中川俊輔, 丸山慎介, 上野健太郎, 岡本康裕, 河野嘉文

    日本小児科学会雑誌   121 ( 6 )   1122   2017.6

     More details

  • 当科で経験したmixed phenotype acute leukemiaの3例

    中川俊輔, 児玉祐一, 西川拓朗, 田邊貴幸, 新小田雄一, 岡本康裕, 河野嘉文

    臨床血液   58 ( 6 )   690‐691(J‐STAGE) - 691   2017.6

     More details

    Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

  • 維持療法中断により総治療期間が延長した小児ALL症例の予後解析―九州山口小児がん研究グループ(Kyushu Yamaguchi Child Cancer Study Group;KYCCSG)ALL96/02研究―

    中島健太郎, 古賀友紀, 岡本康裕, 稲垣二郎, 大園秀一, 糸長伸能, 新小田雄一, 市村卓也, 盛武浩, 野村優子, 中山秀樹, 大賀正一, 河野嘉文

    臨床血液   58 ( 6 )   693(J‐STAGE) - 693   2017.6

     More details

    Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

  • 化学療法中の骨減少症に対してビスフォスフォネート製剤を開始した小児急性リンパ性白血病の3症例

    野村 優子, 西川 拓朗, 岡本 康裕, 河野 嘉文, 廣瀬 伸一

    日本小児血液・がん学会雑誌   53 ( 5 )   474 - 476   2017.3

     More details

    Publisher:(一社)日本小児血液・がん学会  

    小児の急性リンパ性白血病(ALL)では骨減少症を合併しうる。小児におけるビスフォスフォネート(BP)の使用は増えているが、化学療法中のBPの安全性や有効性は確立されていない。今回、九州山口小児がん研究グループALL-96およびALL-02に登録した小児B前駆型ALLのうち、化学療法中にBPを使用した3症例を報告する。3例のALL発症時年齢は3(9歳時に再発)、11、16歳で、いずれも維持療法中の11(第2寛解期)、13、19歳時に骨減少症と診断された。週1回のBP内服(アレンドロン酸35mg、またはリセドロン酸17.5mg)を30〜72ヵ月以上行ったが副作用は認めなかった。2例では、Zスコアが-2.4から-0.2、-3.7から-1.4へと改善した。全例で予定の化学療法を終了し、3年〜5年7ヵ月間寛解を維持している。化学療法中でもBPは安全に使用することができた。(著者抄録)

    DOI: 10.11412/jspho.53.474

  • 移植後シクロフォスファミドを用いた小児HLA半合致末梢血細胞移植におけるシクロフォスファミド薬物動態解析

    西川拓朗, 猪川和朗, あべ松貴成, 中川俊輔, 倉内宏一郎, 児玉祐一, 田邊貴幸, 新小田雄一, 岡本康裕, 河野嘉文

    日本造血細胞移植学会総会プログラム・抄録集   39th   201   2017.2

     More details

  • 交換輸血を行った乳児急性リンパ性白血病

    塩川直宏, 児玉祐一, 永留祐佳, 中川俊輔, 西川拓朗, 田邊貴幸, 岡本康裕, 新小田雄一, 河野嘉文

    日本小児科学会雑誌   121 ( 2 )   466   2017.2

     More details

  • 骨髄非破壊的前処置で骨髄移植を行った放射線誘導海綿状血管腫合併急性リンパ性白血病

    西藤陽, 西川拓朗, 稲葉泰洋, 木下真理子, 楠田政樹, 児玉祐一, 田邊貴幸, 岡本康裕, 盛武浩, 河野嘉文

    日本小児科学会雑誌   121 ( 2 )   426   2017.2

     More details

  • 急性リンパ性白血病患児の寛解導入療法中における体重増加のリスク因子と予防

    関祐子, 関祐子, 岡本康裕, 児玉祐一, 西川拓朗, 田邊貴幸, 中川俊輔, 溝田美智代, 溝田美智代, 河野嘉文

    日本小児内分泌学会学術集会プログラム・抄録集   51st   206   2017

     More details

  • Prognosis of very late relapse in children with ALL: Results of KYCCSG study, ALL-96 and ALL-02

    Noguchi Maiko, Itonaga Nobuyoshi, Nomura Yuko, Shimonodan Hidemi, Ichimura Takuya, Hidaka Yasufumi, Kawano Yoshifumi, Inagaki Jiro, Okamoto Yasuhiro, Koga Yuki, Ozono Shuichi, Shinkoda Yuichi, Nakayama Hideki, Moritake Hiroshi, Hotta Noriko

    J Jpn Soc Pediatr Hematol Oncol   54 ( 5 )   393 - 397   2017

     More details

    Publisher:The Japanese Society of Pediatric Hematology / Oncology  

    &lt;p&gt;[Background] The prognosis of children with acute lymphoblastic leukemia (ALL), who relapsed after a long period from the cessation of the initial treatment, is uncertain, and no treatment strategy has been fully established. [Methods] We analyzed the prognosis of patients who relapsed more than 24 months after the discontinuation of the treatment (very late relapse, VLR) in the KYCCSG protocols, ALL-96 and ALL-02. [Results] A total of 357 patients were enrolled in the two studies and 70 patients (19.6%) relapsed. Eight patients (2.2%) developed VLR with a median remission duration of 37.5 (range, 26–42) months after the cessation of the treatment. At the time of initial diagnosis, six patients were classified into the standard-risk group and two patients into the high-risk group. The sites of relapse were isolated bone marrow (BM) in six patients, isolated testis in one, and a combination of both BM and central nervous system in one. All the eight patients achieved a second complete remission (CR) after reinduction chemotherapy. Three of the eight patients received allogeneic stem cell transplantation (allo SCT). However, one of the three patients had another hematological relapse 11 months after the allo SCT and died. Five patients were successfully treated with chemotherapy only, and therefore, seven patients are alive in CR with a median follow-up duration of 57 (range, 32–92) months after their relapse. [Discussion] Our study indicated that the incidence of VLR is approximately 2%, which is similar to those of previous reports. All patients achieved a second CR after reinduction chemotherapy and seven of the eight patients are alive in CR without a second relapse. Our data suggests that the prognosis of patients with VLR of childhood ALL is favorable.&lt;/p&gt;

    DOI: 10.11412/jspho.54.393

  • Prognosis of very late relapse in children with ALL: Results of KYCCSG study, ALL-96 and ALL-02

    野口磨依子, 野口磨依子, 稲垣二郎, 稲垣二郎, 岡本康裕, 古賀友紀, 大園秀一, 新小田雄一, 中山秀樹, 盛武浩, 堀田紀子, 糸長伸能, 野村優子, 下之段秀美, 市村卓也, 日高靖文, 河野嘉文

    日本小児血液・がん学会雑誌(Web)   54 ( 5 )   393‐397(J‐STAGE)   2017

     More details

▼display all

Presentations

  • Yasuhiro Okamoto, Takuro Nishikawa, Yuichi Kodama, Yuni Yamaki, Koichiro Kurauchi, Takayuki Tanabe, Mami Nagatomo, Risa Yokoyama, Yasuo Suda, Yoshifumi Kawano   Early Diagnosis of Viral Infection/Reactivation Using Sugar Chain-immobilized Gold Nano-particles and qPCR in Patients Undergoing Haematopoietic Stem Cell Transplantation   International conference

    39th Ammual Meeting of the European Group for Blood and Marrow Tranaplantation  39th Ammual Meeting of the European Group for Blood and Marrow Tranaplantation

     More details

    Event date: 2013.4

    Language:English  

    Venue:London, UK  

    国際学会

  • Okamoto Y   Treatment outcome of KYCCSG ALL96 protocol.   International conference

    St. Jude - VIVA Forum in Pediatric Oncology  St. Jude - VIVA Forum in Pediatric Oncology

     More details

    Event date: 2010.3

    Language:English  

    Venue:Singapore  

    国際学会

  • Nagatoshi Y, Okamoto Y, Kosaka Y, Kikuchi A, Kato S, Kigasawa H, Horikoshi Y, Chayama K, Kaneda M, Mori T, Mugishima H, Kawano Y   Pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation: results of a prospective study with 25 children.   International conference

    36th Annual Meeting of the EBMT (European Group for Blood and Marrow Transplantation)  36th Annual Meeting of the EBMT (European Group for Blood and Marrow Transplantation)

     More details

    Event date: 2010.3

    Language:English  

    Venue:Vienna, Austria  

    国際学会

  • Okamoto Y   Introduction of Japanese Protocol for ALL   International conference

    The 26th Korean Society of Pediatric Hematology Oncology Sprig Meeting  The 26th Korean Society of Pediatric Hematology Oncology Sprig Meeting

     More details

    Event date: 2006.4

    Language:English  

    Venue:Soul, Korea  

    国際学会

  • Okamoto Y, Watanabe T, Watanabe H, Onishi T, Kagami S, Kawano Y   Effective sequential harvests of G-CSF mobilized peripheral blood stem cells   International conference

    32nd Annual Meeting of the European Group for Blood and Marrow Transplantation  32nd Annual Meeting of the European Group for Blood and Marrow Transplantation

     More details

    Event date: 2006.3

    Language:English  

    Venue:Hambrug, Germany  

    国際学会

  • Sakaguchi Hirotoshi, Tsuchimochi Taichiro, Deguchi Takao, Ohki Kentaro, Kiyokawa Nobutaka, Hashii Yoshiko, Sekimizu Masahiro, Okamoto Yasuhiro   MYC遺伝子再構成を有さない成熟B細胞性急性リンパ性白血病に関する後方視的研究(A retrospective study on mature B-cell acute lymphocytic leukemia without MYC rearrangement)  

    日本小児血液・がん学会雑誌  2020.10  (一社)日本小児血液・がん学会

  • Abematsu Takanari, Nishikawa Takuro, Nakagawa Shunsuke, Kodama Yuichi, Okamoto Yasuhiro, Kawano Yoshifumi   Inotuzumab OzogamicinとPost-CYを用いたHLA半合致移植が奏功した超早期再発急性リンパ性白血病(Successful treatment of early relapse in acute lymphoblastic leukemia with inotuzumab ozogamicin and HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide)  

    日本小児血液・がん学会雑誌  2019.10  (一社)日本小児血液・がん学会

  • Nagahama Jun, Kodama Yuichi, Abematsu Takanari, Nakagawa Shunsuke, Nishikawa Takurou, Tanabe Takayuki, Shinkoda Yuichi, Okamoto Yasuhiro, Kawano Yoshifumi   Ewing肉腫による脊髄圧迫症状に対し化学療法が奏功した女児例(Chemotherapy for spinal cord compression due to Ewing sarcoma in a girl)  

    日本小児血液・がん学会雑誌  2018.10  (一社)日本小児血液・がん学会

  • 有村 萌, 児玉 祐一, 馬場 悠生, 西川 拓朗, 岡本 康裕, 河野 嘉文   Bリンパ芽球性リンパ腫治療中のメトトレキサート髄腔内注射によるstroke like neurotoxicityを来した女児例  

    日本小児科学会雑誌  2020.10  (公社)日本小児科学会

  • 中川 俊輔, 岡本 康裕, 児玉 祐一, 西川 拓朗, 田邊 貴幸, 河野 嘉文   ALL型治療が奏功したMixed phenotype acute leukemiaの3例  

    日本小児血液・がん学会雑誌  2017.10  (一社)日本小児血液・がん学会

  • 西藤 陽, 西川 拓朗, 稲葉 泰洋, 木下 真理子, 楠田 政樹, 児玉 祐一, 田邊 貴幸, 岡本 康裕, 盛武 浩, 河野 嘉文   骨髄非破壊的前処置で骨髄移植を行った放射線誘導海綿状血管腫合併急性リンパ性白血病  

    日本小児科学会雑誌  2017.2  (公社)日本小児科学会

  • Kodama Yuichi, Okamoto Yasuhiro, Nakagawa Shunsuke, Nishikawa Takuro, Tanabe Takayuki, Kawano Yoshifumi   造血細胞移植後のマルトフィリアによる中心静脈カテーテル関連血流感染症(Central line-associated blood stream infection due to Stenotrophomonas maltophilia after HSCT)  

    臨床血液  2017.9  (一社)日本血液学会-東京事務局

  • 中川 俊輔, 岡本 康裕, 児玉 祐一, 西川 拓朗, 田邊 貴幸, 河野 嘉文   造血幹細胞移植後の一男児例の腸管気腫に対する長期的治療(Long treatment for pneumatosis intestinalis after hematopoietic stem cell transplantation in a boy)  

    臨床血液  2018.9  (一社)日本血液学会-東京事務局

  • 長野 綾香, 春松 敏夫, 武藤 充, 山田 耕嗣, 松久保 眞, 西川 拓朗, 岡本 康裕, 加治 建, 河野 嘉文, 家入 里志   腹腔鏡手術により摘出した副腎VIP分泌性神経芽腫の1例  

    日本小児血液・がん学会雑誌  2020.9  (一社)日本小児血液・がん学会

  • 中島 健太郎, 古賀 友紀, 岡本 康裕, 稲垣 二郎, 大園 秀一, 糸長 伸能, 新小田 雄一, 市村 卓也, 盛武 浩, 野村 優子, 中山 秀樹, 大賀 正一, 河野 嘉文   維持療法中断により総治療期間が延長した小児ALL症例の予後解析 九州山口小児がん研究グループ(Kyushu Yamaguchi Child Cancer Study Group;KYCCSG)ALL96/02研究  

    臨床血液  2017.6  (一社)日本血液学会-東京事務局

  • 井上 一利, 西川 拓朗, 中川 俊輔, 児玉 祐一, 岡本 康裕, 河野 嘉文, 佐々木 裕美, 平木 翼   生検術でmyofibromaと診断された前腕原発spindle cell sarcoma  

    日本小児血液・がん学会雑誌  2018.6  (一社)日本小児血液・がん学会

  • Nakagawa Shunsuke, Okamoto Yasuhiro, Imamura Toshihiko, Imai Chihaya, Kato Motohiro, Kawano Yoshifumi, Shimomura Yasuto, Watanabe Arata, Kikuta Atsushi, Saito Akiko, Horibe Keizo, Manabe Atsushi, Ohara Akira, Koh Katsuyoshi   日本における小児急性リンパ性白血病の寛解導入療法中死亡について(Induction death of children with acute lymphoblastic leukemia in Japan)  

    日本小児血液・がん学会雑誌  2018.10  (一社)日本小児血液・がん学会

  • 楠田 政輝, 櫨木 大祐, 関 祐子, 中川 俊輔, 丸山 慎介, 上野 健太郎, 岡本 康裕, 河野 嘉文   感染性胃腸炎罹患後に心原性ショックを呈した乳児特発性僧帽弁腱索断裂の1例  

    日本小児科学会雑誌  2017.7  (公社)日本小児科学会

  • 下村 育史, 川畑 俊聡, 中川 俊輔, 川村 順平, 岡本 康裕, 河野 嘉文   急速に広がる体幹部の皮下出血で発症したKasabach-Merritt症候群の1例  

    日本小児科学会雑誌  2019.4  (公社)日本小児科学会

  • 中川 俊輔, 吉満 誠, あべ松 貴成, 児玉 祐一, 西川 拓朗, 岡本 康裕, 石塚 賢治, 河野 嘉文   急性骨髄性白血病を発症した遺伝性血小板増多症の1歳女児  

    臨床血液  2019.6  (一社)日本血液学会-東京事務局

  • 関 祐子, 岡本 康裕, 宮園 明典, 中川 俊輔, 児玉 祐一, 西川 拓朗, 河野 嘉文   急性リンパ性白血病治療中の低Na血症の検討  

    日本小児科学会雑誌  2018.2  (公社)日本小児科学会

  • 長濱 潤, あべ松 貴成, 中川 俊輔, 児玉 祐一, 西川 拓朗, 岡本 康裕, 河野 嘉文   当院における再発髄芽腫の治療  

    日本小児科学会雑誌  2018.10  (公社)日本小児科学会

  • 児玉 祐一, 岡本 康裕, あべ松 貴成, 中川 俊輔, 倉内 宏一郎, 西川 拓朗, 田邊 貴幸, 新小田 雄一, 河野 嘉文   当科における髄芽腫標準リスク群の予後  

    日本小児血液・がん学会雑誌  2017.10  (一社)日本小児血液・がん学会

  • あべ松 貴成, 岡本 康裕, 安留 悠希, 中村 達郎, 中川 俊輔, 倉内 宏一郎, 児玉 祐一, 西川 拓朗, 田邊 貴幸, 新小田 雄一, 河野 嘉文   当科における思春期・若年成人(AYA)世代がんについての検討  

    日本小児科学会雑誌  2019.2  (公社)日本小児科学会

  • あべ松 貴成, 岡本 康裕, 中川 俊輔, 児玉 祐一, 西川 拓朗, 田邊 貴幸, 新小田 雄一, 河野 嘉文   当科における再発・難治小児血液腫瘍に対するクロファラビン併用化学療法(Clofarabine-based combination as salvage chemotherapy for hematological malignancies in children)  

    臨床血液  2018.9  (一社)日本血液学会-東京事務局

  • 児玉 祐一, 岡本 康裕, あべ松 貴成, 中川 俊輔, 西川 拓朗, 田邊 貴幸, 新小田 雄一, 河野 嘉文   当科におけるRCC/RCMDに対する造血細胞移植の転帰(Hematopoietic stem cell transplantation in young patients with RCC and RCMD in a single institution)  

    臨床血液  2018.9  (一社)日本血液学会-東京事務局

  • 中川 俊輔, 児玉 祐一, 西川 拓朗, 田邊 貴幸, 新小田 雄一, 岡本 康裕, 河野 嘉文   当科で経験したmixed phenotype acute leukemiaの3例  

    臨床血液  2017.6  (一社)日本血液学会-東京事務局

  • 有村 萌, 児玉 祐一, あべ松 貴成, 中川 俊輔, 西川 拓朗, 岡本 康裕, 海野 嘉文   左外転・動眼神経麻痺を呈した副咽頭間隙原発の卵黄嚢腫瘍の男児  

    日本小児科学会雑誌  2020.2  (公社)日本小児科学会

  • Okamoto Yasuhiro, Nishikawa Takuro, Kodama Yuichi, Nakagawa Shunsuke, Tanabe Takayuki, Kawano Yoshifumi   小児難治性白血病および血液疾患に対するハプロ移植の成績(Haplo-transplants in children with refractory leukemia or non-malignant hematological disorders)  

    臨床血液  2017.9  (一社)日本血液学会-東京事務局

  • Yoshida Nao, Takahashi Yoshiyuki, Yabe Hiromasa, Kobayashi Ryoji, Watanabe Kenichiro, Kudo Kazuko, Yabe Miharu, Miyamura Takako, Koh Katsuyoshi, Kawaguchi Hiroshi, Goto Hiroaki, Fujita Naoto, Hara Junichi, Okamoto Yasuhiro, Kato Koji, Inoue Masami, Suzuki Ritsuro, Atsuta Yoshiko, Kojima Seiji   小児後天性造血不全症に対する同種骨髄移植の至適前処置法の検討 FLU/MEL vs.FLU/CY(Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide)  

    日本小児血液・がん学会雑誌  2019.10  (一社)日本小児血液・がん学会

  • Ishimaru Sae, Okamoto Yasuhiro, Imai Chihaya, Sakaguchi Hirotoshi, Taki Tomohiko, Hasegawa Daisuke, Cho Yuko, Kakuda Harumi, Sano Hideki, Manabe Atsushi, Imamura Toshihiko, Kato Motohiro, Arakawa Yuki, Shimonodan Hidemi, Sato Atsushi, Suenobu Souichi, Inukai Takeshi, Watanabe Arata, Kawano Yoshifumi, Kikuta Atsushi, Horibe Keizo, Ohara Akira, Koh Katsuyoshi   小児低2倍体急性リンパ性白血病の予後に関する調査研究 4グループ合同調査(A nationwide survey of pediatric hypodiploid acute lymphoblastic leukemia in Japan)  

    日本小児血液・がん学会雑誌  2018.10  (一社)日本小児血液・がん学会

  • 藤崎 陽介, 中村 文彦, 伊藤 宗一朗, 東 龍太郎, 上山 友子, 吉浦 敬, 岡本 康裕, 河野 嘉文   小児の脊髄退形成星細胞腫に対する放射線治療の1例  

    Japanese Journal of Radiology  2019.2  (公社)日本医学放射線学会

  • Ikeda Yuhachi, Tasaka Keiji, Daifu Tomoo, Kato Itaru, Kikuta Atsushi, Sato Atsushi, Tomizawa Daisuke, Okamoto Yasuhiro, Takita Junko, Taga Takashi   小児がん治療における日常診療の全国多施設アンケート調査(Daily supportive care for the patient with pediatric cancer in Japan)  

    日本小児血液・がん学会雑誌  2020.10  (一社)日本小児血液・がん学会

  • 楠田 政輝, 櫨木 大祐, 関 祐子, 中川 俊輔, 丸山 慎介, 上野 健太郎, 岡本 康裕, 河野 嘉文   大動脈弓離断複合術後にWest症候群を発症し、ACTH療法後に急性呼吸循環不全を来した乳児例  

    日本小児科学会雑誌  2017.6  (公社)日本小児科学会

  • 光延 拓朗, 西川 拓朗, 中川 俊輔, 児玉 祐一, 田邊 貴幸, 岡本 康裕, 河野 嘉文   化学療法後寛解期に食道閉鎖をきたした未分化大細胞リンパ腫  

    日本小児科学会雑誌  2018.2  (公社)日本小児科学会

  • Okamoto Yasuhiro, Nakagawa Shunsuke, Abematsu Takanari, Kodama Yuichi, Nishikawa Takuro, Tanabe Takayuki, Shinkoda Yuichi, Kawano Yoshifumi   再発固形腫瘍の予後解析(Outcomes after first relapse in children with solid tumors in an era without novel treatments)  

    日本小児血液・がん学会雑誌  2017.10  (一社)日本小児血液・がん学会

  • Okamoto Yasuhiro   再発した小児ALLに対する2回目の同種造血SCT(Second allogeneic hematopoietic SCT for relapsed ALL in children)  

    日本小児血液・がん学会雑誌  2020.10  (一社)日本小児血液・がん学会

  • 杉田 光士郎, 川野 孝文, 山田 耕嗣, 山田 和歌, 児玉 祐一, 西川 拓朗, 岡本 康裕, 加治 建, 河野 嘉文, 家入 里志   仙尾部胚細胞腫瘍15例の診療経験による臨床的検討  

    日本小児血液・がん学会雑誌  2020.10  (一社)日本小児血液・がん学会

  • 塩川 直宏, 児玉 祐一, 永留 祐佳, 中川 俊輔, 西川 拓朗, 田邊 貴幸, 岡本 康裕, 新小田 雄一, 河野 嘉文   交換輸血を行った乳児急性リンパ性白血病  

    日本小児科学会雑誌  2017.2  (公社)日本小児科学会

  • 光延 拓朗, 西川 拓朗, 中川 俊輔, 児玉 祐一, 岡本 康裕, 河野 嘉文   中枢神経病変に対しbrentuximab vedotinと大量methotrexate療法を併用し、寛解した難治性未分化大細胞リンパ腫  

    臨床血液  2019.5  (一社)日本血液学会-東京事務局

  • Miyahara Emiko, Nishikawa Takuro, Ikawa Kazuro, Ushikai Miharu, Kawaguchi Hiroaki, Okamoto Yasuhiro, Morikawa Norifumi, Horiuchi Masahisa, Kawano Yoshifumi   マウスにおける大量シクロホスファミドの薬物動態及び毒性の評価(Pharmacokinetics and toxicological evaluation of high-dose cyclophosphamide in mice)  

    臨床血液  2017.9  (一社)日本血液学会-東京事務局

  • 岡本 康裕   ダウン症に合併した急性リンパ性白血病  

    日本小児血液・がん学会雑誌  2017.10  (一社)日本小児血液・がん学会

  • Rindiarti Almitra, Okamoto Yasuhiro, Nakagawa Shunsuke, Abematsu Takanari, Kodama Yuichi, Nishikawa Takuro, Kawano Yoshifumi   セレコキシブの血管内皮細胞株における増殖抑制と血管新生抑制作用(Celecoxib showed anti-proliferation and anti-angiogenesis effect on endothelial cell line)  

    日本小児血液・がん学会雑誌  2019.10  (一社)日本小児血液・がん学会

  • あべ松 貴成, 西川 拓朗, 中川 俊輔, 児玉 祐一, 岡本 康裕, 河野 嘉文   ギルテリチニブを造血幹細胞移植前後で投与し、寛解を維持しているFLT3-ITD、NUP98-NSD1共発現の急性骨髄性白血病M4の14歳男子例  

    臨床血液  2020.10  (一社)日本血液学会-東京事務局

  • Abematsu Takanari, Nishikawa Takuro, Nakamura Tatsuro, Matsuishi Toshiya, Nakagawa Shunsuke, Kodama Yuichi, Okamoto Yasuhiro, Kawano Yoshifumi   ギルテリチニブが著効した、FLT3-ITDとNUP98-NSD1が共発現の小児急性骨髄性白血病の2例(Two cases of pediatric acute myeloid leukemia with FLT3-ITD and NUP98-NSD1 co-expression that responded to gilteritinib treatment)  

    日本小児血液・がん学会雑誌  2020.10  (一社)日本小児血液・がん学会

  • 堀 壽成, 山田 朋美, 下村 保人, 今井 千速, 百名 伸之, 多賀 崇, 堀越 泰雄, 山中 純子, 渡邉 健一郎, 小川 淳, 七野 浩之, 野村 恵子, 犀川 太, 西村 良成, 井上 彰子, 岡田 雅彦, 上山 潤一, 岩井 朝幸, 矢野 道広, 陳 基明, 岡本 康裕, 横田 昇平, 鶴澤 正仁, 菊田 敦, 渡辺 新, 小児がん・白血病研究グループ   CCLSG ALL2004研究におけるComplete Remission症例のMRDによる解析  

    日本小児血液・がん学会雑誌  2017.10  (一社)日本小児血液・がん学会

  • 中村 達郎, 西川 拓朗, 松石 登志哉, 中川 俊輔, 児玉 祐一, 岡本 康裕, 河野 嘉文   治療関連骨髄異形成症候群(monosomy7)からフィラデルフィア染色体陽性急性骨髄性白血病に進展した12歳女児  

    臨床血液  2021.6  (一社)日本血液学会-東京事務局

     More details

    Language:Japanese  

  • 濱田 平一郎, 古川 良尚, 舞木 弘幸, 宮元 珠華, 櫛山 歩, 外室 喜英, 原口 安江, 中島 篤人, 古城 剛, 橋ノ口 寛仁, 江口 奈津希, 松井 宏樹, 岡本 康裕, 吉満 誠   COVID-19禍により開始された骨髄濃縮・凍結保存処理が生着に与える影響  

    日本輸血細胞治療学会誌  2021.5  (一社)日本輸血・細胞治療学会

     More details

    Language:Japanese  

▼display all